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The interaction between cancer cells and the extracellular matrix 
(ECM) holds a special position in tumor progression. While the ECM 
modulates cancer initiation and progression, cancer cells are able to remodel 
the ECM to facilitate their survival, migration and invasion. During metastasis, 
cancer cells develop a special ability called anoikis resistance or extracellular 
matrix (ECM)-independent survival to thrive in the condition without ECM 
attachment. Actin cytoskeleton plays an important role in anoikis resistance of 
cancer cells, with unknown modes of action. In this study, we investigated the 
effects of gelsolin, a well-known regulator of actin cytoskeleton, on cancer 
cell survival in an anoikis condition and the underlying mechanism of those 
effects. 
We showed that gelsolin protected colorectal cancer HCT 116 cells 
from apoptosis and promoted HCT 116 cell survival in an anoikis model. Our 
data suggested that gelsolin exerted the effects by upregulating fibronectin 
expression and secretion in HCT 116 cells. Conditioned media obtained from 
gelsolin over-expressing cells protected HCT 116 cells against apoptosis in the 
anoikis condition, suggesting that gelsolin-overexpressing cells secreted 
factors that promoted cancer survival. On the other hand, fibronectin 
expression and secretion, which were regulated by gelsolin, protected cancer 
cells against apoptosis and promoted cancer cell survival through Akt 
signaling. Fibronectin also rescued the apoptotic effects of gelsolin knock-
down in cells cultured in the anoikis condition. 
viii 
 
In addition, our results suggested that gelsolin upregulated fibronectin 
expression in HCT 116 cells through activation of the transcription factor 
nuclear factor kappa B (NFB). NFB activity was significantly enhanced in 
gelsolin-overexpressing cells and attenuated in gelsolin-knockdown cells. 
Activation of NFB by tumor necrosis factor alpha (TNFled to increased 
fibronectin expression in HCT 116 cells, whilst inhibition of NFB attenuated 
fibronectin expression. Additionally, upregulation of fibronectin by gelsolin 
could be attenuated by NFB inhibition. Fibronectin expression was also 
upregulated by the early growth response proteins 1 (EGR-1). However, 
gelsolin did not affect either EGR-1 expression or EGR-1 activity. These 
findings suggest that gelsolin upregulated fibronectin expression via NFB but 
not EGR-1 pathway. 
In summary, our findings reveal a novel role of gelsolin in promoting 
ECM-independent cancer cell survival by upregulating fibronectin expression 





LIST OF FIGURES 
Figure 1.1. Gelsolin structure 3 
Figure 1.2. Gelsolin promotes the regulated-secretion of insulin in 
mouse pancreatic β-cells 
9 
Figure 1.3. A schematic illustration of extracellular matrix structure 
in connective tissues 
14 
Figure 1.4. Roles of extracellular matrix in cell biology 18 
Figure 1.5. Fibronectin structure 22 
Figure 1.6. Integrin signaling pathways 26 
Figure 3.1. Fibronectin expression and secretion in colorectal cancer 
cells 
57 
Figure 3.2. Modulation of gelsolin expression in HCT 116 cells 60 
Figure 3.3. Gelsolin overexpression upregulates fibronectin expression 
and secretion by HCT 116 cells 
64 
Figure 3.4. Gelsolin knock-down attenuates fibronectin expression and 
secretion in HCT 116 cells 
68 
Figure 3.5. Gelsolin overexpression protects HCT 116 cells from cell 
death in anoikis model (flow cytometric analysis of propidium iodide 
staining) 
71 
Figure 3.6. Gelsolin knock-down stimulates cell death of HCT 116 
cells in anoikis model (flow cytometric analysis of propidium iodide 
staining) 
73 
Figure 3.7. Conditioned media from gelsolin-overexpressing cells 
protect cancer cells from anoikis-induced apoptosis 
78 
Figure 3.8. Fibronectin rescued the effects of gelsolin knock-down on 
apoptosis in HCT 116 cells (flow cytometric analysis of annexin-V 
staining) 
83 
Figure 3.9. Fibronectin expression and secretion protects HCT 116 
cells from apoptosis in anoikis model 87 
Figure 3.10. Fibronectin promotes Akt signaling in HCT 116 cells 90 
Figure 4.1. HGF stimulates fibronectin expression in HCT 116 cells 104 
x 
 
Figure 4.2. HGF stimulates EGR-1 expression in HCT 116 cells 106 
Figure 4.3. Gelsolin overexpression does not affect EGR-1 expression 
and transcriptional activity 
110 
Figure 4.4. Gelsolin knock-down does not affect EGR-1 expression 
and transcriptional activity 
111 
Figure 4.5. NFB inhibitor BAY 11-7085 attenuates fibronectin 
expression in HCT116 cells 
113 
Figure 4.6. TNF stimulates fibronectin expression in HCT 116 cells 115 
Figure 4.7. Gelsolin overexpression promotes NFB activity but not 
NFB expression. 
118 
Figure 4.8. Gelsolin knock-down attenuates NF B activity but not 
NFB expression 
119 
Figure 4.9. Gelsolin-upregulated fibronectin expression is attenuated 
by NFB inhibition 
122 
Figure 5.1 Schematic illustration showing the summary of the key 









PIP2 Phosphatidylinositol 3,4 or 4,5-bisphosphate 
SDF-1 Stromal derived factor 1 
PARP Poly-adenosine diphosphate ribose polymerase 
DNase Deoxyribonuclease 
HIF1 Hypoxia-inducible factor-1alpha 
VDAC Voltage-dependent anion channel 
PLD Phospholipase D 
PLC Phospholipase C 




Soluble N-ethylmaleimide-sensitive factor attachment 
Receptors 
Syntaxin 4 
VAMP2 Vesicle-associated membrane protein 2 
AP-1 Activator protein-1 
NFκB Nuclear factor kappa B 
ATF-1 Activating transcription factor-1 
ECM Extracellular matrix 
MMP Matrix metalloproteinase 
ADAMTS A disintegrin and metalloproteinase with 
Thrombospondin motifs 
LOX Lysyl oxidase 
EIIIA or EDA Type III extra domains A 
EIIIB or EDB Type III extra domains B 
TNF Tumor necrosis factor alpha 
bFGF Basic fibroblast growth factor 
PKC Protein kinase C alpha 
HBV Hepatitis B virus 
HBVxAg HBVx antigen 
EGR-1 Early growth response 1 
xii 
 
HGF Hepatocyte growth factor 
MAPK Mitogen-activated protein kinase 
NAB2 NGFI-A binding protein 
UTR Untranslated region 
LC3 Light chain 3 of microtubule-associated proteins 
1A/1B 
ER Endoplasmic reticulum 
RGD Arg-Gly-Asp 
FAK Focal adhesion kinase 
PI3K Phosphoinositol 3 kinase 
HPCs Hematopoietic progenitor cells 
Bcl-2 B-cell lymphoma 2 
p-Akt Phospho-Akt 
IB Inhibitor of kappa B 
 
 












 2   
 
1.1. GELSOLIN 
1.1.1.  Gelsolin structure 
Gelsolin (GSN) is a member of the gelsolin superfamily of actin-binding 
proteins, with a molecular weight of about 80-84kDa. Three isoforms of 
gelsolin have been identified including plasma gelsolin, cytoplasmic gelsolin 
and gelsolin-3. The gelsolin isoforms are encoded by one single gene. 
Transcription of the gelsolin gene is controlled by promoters at different sites, 
resulting in alternative splicing variants. Compared to cytoplasmic gelsolin, 
the plasma isoform has an additional signal peptide of 25-amino acid and 
plasma extension.  Gelsolin-3 has extra 11-amino acids at the N-terminus 
compared to cytoplasmic gelsolin [1, 2]. While cytoplasmic gelsolin is 
expressed in all tissues, gelsolin-3 is only detected in brain, lung and testis [3]. 
Gelsolin consists of 6 domains (G) with binding sites for actin and Ca2+. 
Domains G1 and G4 have binding sites for actin monomers (G-actin), while 
domain G2 contains binding sites for actin filaments (F-actin) [2]. In the 
inactive form, the helix tail of G6 interacts with G2 to form a latch, masking 
actin-binding sites on the gelsolin molecule. Upon activation by Ca2+, the latch 
between G2 and G6 opens, allowing conformational rotation of G3 and G6 
compared to G1 and G4, hence exposing actin-binding sites for capping and 











Figure 1.1. Gelsolin structure. (A) The gelsolin gene encoding plasma and 
cytoplasmic gelsolin isoforms. (B) Conformational changes of gelsolin for 
capping and severing actin filaments. Figure is from a paper by Li G.H. et al, 
Med Res Rev, 2012. 32(5): p. 999-1025 [2]. 
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1.1.2.  Functions of gelsolin in cell biology 
The three isoforms of gelsolin, including plasma gelsolin, gelsolin-3 and 
cytoplasmic gelsolin, serve different functions in cell biology. The main role 
of plasma gelsolin is to scavenge actin filaments generated from necrotic cells, 
which are toxic to living cells. Plasma gelsolin was also shown to transport 
inflammatory factors to their receptors, and hence plays a role in immune 
system. Indeed, plasma gelsolin level decreases in patients with sepsis, trauma 
or liver injury. Therefore, plasma gelsolin was proposed to be a prognostic 
biomarker for the above-mentioned diseases. Gelsolin-3 has limited 
expression in brain, lung and testis with unknown cellular and physiological 
functions. In this study we focused on the most common form of gelsolin, the 
cytoplasmic isoform, and its roles in cell biology will be discussed in the 
following part. 
1.1.2.1.  Roles of gelsolin in normal cell biology 
Regulation of actin dynamics: 
Gelsolin is well-known as an actin regulator, playing important roles in 
regulating actin dynamics. Upon binding to an actin filament, gelsolin severs 
the filament into two and remains to cap the newly severed end (or barbed 
end), and hence inhibits polymerization of the filament. In the presence of 
phosphatidylinositol 3,4 or 4,5-bisphosphate (PIP2), which competitively 
binds to barbed ends, gelsolin is released from its binding with actin filaments. 
The length of actin filaments is maintained, in stable conditions, by continuous 
addition of actin monomers to the barbed ends and deletion of monomers from 
the pointed ends. By capping and inhibiting the addition of monomers at the 
barbed ends, gelsolin directly depolymerizes actin filaments, creating 
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shortened filaments and more newly-severed ends. The newly-generated 
barbed ends, when uncapped by PIP2, serve as acting sites for further 
polymerization and/or branch formation [5, 6], which induce membrane 
protrusion for locomotion. On the other hand, by regulating the actin network 
near the plasma membrane, gelsolin modulates stress fibers that affect the 
shape of a cell. As a result, gelsolin promotes cell motility and defines cell 
shape. Indeed, overexpression of gelsolin in fibroblasts stimulates cell 
migration. Hematopoietic stem cells with low gelsolin expression migrate 
slower in response to the chemokine stromal-derived factor 1 (SDF-1) than 
those with high gelsolin expression [7-10]. In gelsolin knock-out mice, 
osteoclasts were unable to form podosomes for cell adhesion, leading to 
decreased osteoclastic motility in both basal and osteopontin-induced 
conditions [11, 12]. 
 
Apoptosis: 
Gelsolin shows contradictory effects on apoptosis, depending on stimuli 
and cell types. Upon stimulation by apoptotic stimuli, gelsolin is cleaved by 
caspases-3, -7 or -9 at the 252-253 residues to generate a 39 kDa N-terminal 
half and a 41 kDa C-terminal half. Gelsolin cleavage was observed 
concomitantly with poly-adenosine diphosphate ribose polymerase (PARP) 
disruption, which is associated with enhanced apoptosis in vivo [2]. The N-
terminal half binds to actin filaments independent of Ca2+, resulting in 
uncontrolled apoptosis. The N-terminal half of gelsolin also stimulates 
apoptosis by competing with deoxyribonuclease (DNase) I for binding to actin. 
DNase I is thus dissociated from its binding to actin and induces apoptotic 
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degradation. In addition, gelsolin was suggested to activate DNase I for 
apoptosis via its association with both DNases I and hypoxia-inducible factor-
1alpha (HIF1), which is a possible regulator of DNases I [13]. 
On the other hand, full-length gelsolin and the C-terminal half of 
gelsolin have been observed to exert anti-apoptotic effects. Gelsolin was 
shown to inhibit mitochondria potential loss, resulting in blockage of voltage-
dependent anion channel (VDAC), which is, in normal conditions,  
responsible for the release of cytochrome c from mitochondria to cytosol for 
caspase activation, and ultimately apoptosis [14, 15]. 
 
Signal transduction: 
Besides its functions on actin remodeling, gelsolin also regulates 
different aspects of cell biology by its involvement in different signaling 
pathways. Gelsolin physically interacts with phospholipase D (PLD) to 
activate both PLD downstream signals and actin remodeling [16]. Gelsolin 
also modulates PLC signaling by competing with phospholipase C (PLC) beta 
and gamma in binding to PIP2. Inhibition of PLC’s association with its 
substrate, PIP2, leads to suppression of downstream signals of PLC [7]. In 
addition, a study by Azuma et al [17] suggested that gelsolin is a downstream 
effector of EGF-induced Rac activation. Experiments on Gsn-/- fibroblasts 
demonstrated that Rac was overexpressed when gelsolin was knocked out. Rac 
overexpression in this condition was postulated to compensate for the 
decreased motility induced by gelsolin knock-out. However the compensatory 
overexpression of Rac was unable to completely reverse the effects of gelsolin 
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depletion on cell ruffling and motility, indicating that the gelsolin plays an 
essential role in Rac signaling. 
 
Transcriptional co-activation: 
Mounting evidence has shown the involvement of gelsolin in co-
regulating several transcription factors or transcription co-activators. Gelsolin 
interacts with androgen receptor (AR) at DNA-binding and ligand-binding 
sites of AR molecule in the nucleus of human prostate cancer cells, resulting 
in enhanced AR activity. Interestingly, in vitro and in vivo studies showed that 
gelsolin expression was highly detected after treatment with androgen 
deprivation or AR antagonists. This suggests that inhibition of AR activity 
may be compensated by high gelsolin expression, which aids to magnify AR 
activity, hence to contribute to prostate cancer resistance. Targeting gelsolin, 
therefore, is perhaps a possible strategy to treat prostate cancer recurrence [18]. 
In thyroid cancer mouse model, the C-terminus of gelsolin was shown to 
interact with thyroid hormone receptor-1 at the DNA binding sequence of 
thyroid hormone receptor. The interaction with gelsolin inhibited the effects of 
thyroid hormone receptor on tumor progression [19]. 
Recently, gelsolin has been shown to serve as an activity checkpoint of 
the transcription co-activators YAP and TAZ, which are important regulators 
of cell survival and proliferation [20]. In normal condition, YAP and TAZ 
localize in cytoplasm in binding with gelsolin. When cells are stimulated by 
mechanical stresses or stiffness changes of ECM, gelsolin releases YAP and 
TAZ for their translocation to the nucleus, where they bind TEAD 
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transcription factors for transcription of target genes. Therefore, gelsolin 
indirectly affects transcription of various genes downstream of YAP and TAZ.  
Gelsolin also inhibits tumor suppressor protein p53, which acts as a 
transcription factor to regulate cell differentiation and apoptosis. By 
interacting with p53 and retaining it in cytoplasm, gelsolin suppresses nuclear 
translocation of p53 in hepatocarcinoma cells, resulting in attenuation of 
apoptosis [21]. 
 
Regulation of vesicle secretion: 
Cytoskeleton plays an important part in exocytosis of secretory vesicles. 
At the proximity of plasma membrane, actin filaments form a meshwork that 
blocks the transport of secretory vesicles to plasma membrane for fusion and 
secretion [22]. By regulating actin dynamics, gelsolin indirectly promotes 
movement of secretory vesicles to exocytosis sites on plasma membrane. 
Gelsolin also plays an important role in regulated secretion, a process by 
which secretory vesicles bind to soluble N-ethylmaleimide-sensitive factor 
attachment receptors (SNARE) upon stimulation before being secreted outside.  
In basal conditions, gelsolin interacts with Sytaxin 4 (Syn4), a SNARE protein, 
to hinder binding of insulin vesicles to Syn4. When cells are stimulated by 
glucose or potassium chloride, gelsolin is disconnected from the interaction 
with Syn4. Thus, insulin vesicles are able to bind to Syn4, and then fuse with 
plasma membrane for exocytosis [23]. A summary of these findings are 
summarized in Figure 1.2.  
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Figure 1.2. Gelsolin promotes the regulated-secretion of insulin in mouse 
pancreatic β-cells.  In basal condition, gelsolin interacts with Syn4, a SNARE 
protein, on plasma membrane to hinder the fusion of insulin vesicles to plasma 
membrane. When cells are stimulated by glucose, gelsolin is dissociated from 
the interaction with Syn4. The vesicle-associated membrane protein 2 
(VAMP2), a SNARE protein on insulin secretory vesicles, binds to Syn4 for 
fusion of insulin secretory vesicles with plasma membrane and insulin vesicles 
are secreted outside.  
 
1.1.2.2. Roles of gelsolin in tumor biology 
Numerous studies have shown that gelsolin is involved in cancer 
development. However, the exact roles of gelsolin in tumor biology are still 
under debate. Decreased expression of gelsolin was observed in some cancers 
such as colon, gastric, breast and lung cancers [24-27], suggesting the possible 
roles of gelsolin as a tumor suppressor. The findings were supported by 
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several studies in which overexpression of gelsolin reduced proliferation of 
bladder cancer cells as well as attenuated carcinogenesis in a mouse model 
[28]. In addition, gelsolin siRNA knock-down induced epithelial-
mesenchymal transition in human mammary cells, resulting in enhanced 
cancer progression [29]. 
However mounting evidence suggested an opposite role of gelsolin in 
cancer progression, based on the fact that gelsolin is highly expressed in other 
cancers. Recent studies have provided more information to explain the 
contradictory results regarding gelsolin expression in cancers. Although 
gelsolin expression is decreased in some tumors, its higher levels correlate 
with more advanced stages of the diseases. A study with non-small lung cell 
carcinoma tissues demonstrated that high gelsolin expression correlated with 
high recurrence risk of cancers in lung [30, 31]. Similar correlation was also 
found in cancers in kidney [32] and urinary track [33]. Therefore, gelsolin was 
recommended to be used as a biomarker for progression and recurrence of 
these cancers. Interestingly, gelsolin was highly detected at the invasive front 
of liver metastatic tissues of colorectal cancers. Gelsolin stimulated cancer 
invasion and metastasis by up-regulating invasion-promoting factors such as 
urokinase plasminogen activator and its receptor, and/or by repressing E-
cadherin expression [24, 34]. These results highlight an important role of 
gelsolin in cancer invasion and metastasis. The findings also suggest that, 
gelsolin serves as a tumor suppressor at primary sites, but when re-emerges, it 
confers tumor-promoting roles by stimulating invasion and metastasis. 
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1.1.3.  Regulation of gelsolin expression 
Gelsolin has been found with decreased expression in various cancers. 
However, no mutant regulatory sites or regions in the gelsolin gene have been 
identified, suggesting that downregulation of the gesolin gene is not by 
mutation but other mechanisms.  
Mielnicki et al. [35] was the first group to report the downregulation of 
gelsolin by epigenetic modification via histone deacetylation. Normally, 
histone deacetylation is catalyzed by histone deacetylases, resulting in 
increased positive charge of histone tails, strengthening histone-DNA binding 
and stimulating post-translational modification by histone methyl transferases. 
Thus, histone deacetylation blocks accessibility of transcriptional complexes 
to DNA, leading to gene silencing [36]. Gelsolin expression in breast cancer 
was shown to be upregulated by inhibition of histone deacetylases [35]. 
Subsequent studies on cervical cancer cells [37], urinary cancer cells [38] and 
gastric cancer tissues [39] confirmed the regulatory effect of histone 
deacetylation on gelsolin depression in those cancers. On the other hand, 
interaction of transcriptional complexes to DNA can also be interfered by 
DNA methylation, a process characterized by addition of methyl groups to 
cytosine in CpG islands. Hyper-methylation in intron 1 of the gelsolin gene 
was observed, suggesting that gelsolin is probably downregulated by DNA 
methylation [35]. 
Besides the epigenetic modification mentioned above, some 
transcription factors are also involved in regulation of the gelsolin gene. 
Sequence analysis of the gelsolin gene revealed interacting sites for the 
TATA-binding protein (TBP), specificity protein 1 (Sp1), activator protein-1 
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(AP-1), and nuclear factor kappa B (NFκB). Indeed, a study in HeLa cells 
confirmed that Sp1 bound to gelsolin promoter to upregulate the gelsolin gene 
[40]. Additionally, gelsolin was downregulated in breast cancer by interacting 
with the activating transcription factor-1 (ATF-1) [41]. 
At protein level, a study in pancreatic cancer showed that gelsolin was 
regulated by ubiquitin-dependent proteosomal degradation [42]. The 
conclusion was supported by the evidence demonstrating that gelsolin 
expression was suppressed in the early stages of pancreatic cancer at protein 
level but not mRNA level, suggesting post-translational down-regulation of 
gelsolin. The finding was further confirmed by data showing that poly-
ubiquitinated gelsolin was detected in pancreatic cancer cells and inhibition of 
26s proteasome significantly increased gelsolin expression.   
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1.2. EXTRACELLULAR MATRIX 
1.2.1.  Extracellular matrix composition and structure 
Extracellular matrix (ECM) is a complex structure present in all tissues 
(Figure 1.3). Basically ECM consists of 2 main structural components, which 
are fibers and interstitial matrix. ECM fibers are made of glycoproteins, such 
as collagens and elastin, forming a flexible fibrous scaffold or basement 
membrane. Interstitial matrix or ground substance is made of amorphous 
proteoglycans (e.g. aggrecan, syndecan),  glycosaminoglycans (e.g. dermatan 
sulfate, keratan sulfate, hyaluronan) and adhesive glycoproteins (e.g. 
fibronectin, laminin). Interstitial matrix interacts with both basement 
membrane and cells in the matrix vicinity. The proportion of fibers and 
interstitial matrix of the ECM varies between different tissues, contributing to 
tissue-specific characteristics such as strength, elasticity and stickiness. [43] 
Although ECM proteins are particularly diverse, they are similar in a 
way that they all consist of multi-domains with high molecular weight. Most 
of ECM proteins are normally decorated with glycosylation, which makes 
ECM components greatly bigger and more complex. Multi-domains of ECM 
proteins are repeated homologous structures, which share similar functions 
and may work independently or together to exert certain functions. Multi-
domains of different proteins can also interact with each to form fiber 











Figure 1.3. A schematic illustration of extracellular matrix structure 
in connective tissues 
Adapted figure from a chapter by Engel J. et al. (The Extracellular Matrix: an 
Overview, R.P. Mecham, Editor. 2011, Springer Berlin Heidelberg. p. 1-
39.)[44] 
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1.2.2.  Extracellular matrix remodeling 
ECM is not a static structure as usually being thought. In fact, it is 
extremely dynamic at microscopic level due to the constant remodeling of 
ECM components. ECM remodeling consists of formation steps, which are 
secretion and deposition, and deformation processes, which are modification 
and degradation. A balance of secretion, deposition, modification and 
degradation is always maintained in normal condition. [44] 
 
1.2.2.1.  Secretion and deposition of ECM components 
ECM proteins are secreted locally by resident cells in the matrix, which 
are mostly fibroblasts and probably some epithelial cells. Except for collagen, 
secretion of other ECM proteins is poorly understood. Thus, information about 
synthesis, secretion and deposition of collagen will help to understand possible 
productional mechanisms of other ECM proteins.  
Large precursors of collagen peptides are synthesized on rough-
ribosomes and transported to endoplasmic reticulum due to signal peptides in 
N-termini. Then the precursors are hydroxylated at selected prolines and 
lysines. Some are also glycosylated at specific hydroxylysines. The precursors 
interact via hydrogen bonds to form higher structures such as pro-collagen, a 
stable triple-stranded helix. After secretion, pro-collagen molecules are 
converted to collagen by enzyme-cleavage of pro-peptides. Collagen 
molecules, which are about 1000-fold more insoluble than pro-collagen, self-
assemble to form large collagen fibrils. Fibrils are formed extracellularly at the 
promixity of plasma membrane where secretory vesicles fuse with cell surface 
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in exocytosis. Covalent cross-links between ECM fibers at lysine residues 
further fortify fibril structures. Then, ECM-secreting cells such as fibroblasts 
interact with the secreted molecules mechanically and chemically to compact 
the collagen fibrils into sheet-like or packed structures and push other secreted 
proteins into that meshwork. In turn, the meshwork modulates fibroblast 
distribution as it occupies most of the area in the proximity. Different fibrils 
such as inelastic collagen and elastic fibrils can interweave with each other to 
further enrich the complexity and plasticity of the ECM.  
 
1.2.2.2.  Modification and degradation of ECM components 
The ECM is degraded by a wide range of matrix-degrading enzymes, 
including: 
- Metalloproteinase family such as matrix metalloproteinase (MMP), a 
disintegrin and metalloproteinase with thrombospondin motifs 
(ADAMTS) families and their inhibitors; 
- Other proteases such as heparanase, cathepsins, hyaluronidases, 
serine and threonine proteases. [45] 
Most of matrix-degrading enzymes have their specific targets, for 
example proteoglycans, fibronectin and laminin are targeted by MMP-3 and -
10 and serine protease plasmin, whilst collagen III is degraded by MMP-1, 
collagen I and II is degraded by MMP-8 and -13 [46]. Matrix-degrading 
enzymes cause cleavage and alteration of ECM structure. The main function 
of these processes is to ensure proper disposal of unwanted proteins during 
development. Any changes in the homeostasis of the enzymes will affect ECM 
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structure and ultimately tissue functions. For example, lysyl oxidase (LOX) 
and lysyl hydroxylases modify formation of collagen and elastin cross-linking, 
resulting in altered physical properties of tissues such as enhanced tensile 
strength and stiffness [47]. 
 
1.2.3. Roles of extracellular matrix in cell biology 
1.2.3.1. Roles of ECM in normal cell biology 
The ECM plays intricate and crucial roles in cell biology (Figure 1.4). In 
normal conditions, ECM serves as a platform for cell anchorage, division, 
proliferation and migration. Cells anchor to the ECM when it comes to 
asymmetry division (step 1). Depending on the conditions, the ECM may be a 
barrier against cell migration, or may act as a track for cell movement (step 2 
and 3). The ECM is also a reservoir of growth factors, which are secreted and 
deposited into the ECM (step 4). The growth factors trigger cells directly or 
are presented to cells via ECM proteins (step 5 and 6). Some ECM proteins in 
the proximity of cells, such as fibronectin, or some ECM fragments are able to 
directly influence cell survival, proliferation or migration (step 7). The ECM 
also exerts biomechanical forces via actin cytoskeleton to affect changes in 
cell behaviors (step 8) [48]. 
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Figure 1.4. Roles of extracellular matrix in cell biology.  
A figure selected from a paper by Lu P. et al. (J Cell Biol, 2012. 196(4):  
p. 395-406) [48] 
 
1.2.3.2. Roles of ECM in tumor biology 
During normal cellular development, the homeostasis of the ECM is 
maintained by a regulatory system that ensures the balance of formation and 
deformation processes. Disruption of that regulatory system is often observed 
in some abnormal conditions such as cancer. The ECM plays important roles 
in the initiation, progression and recurrence of different cancers. 
 
Cancer initiation: 
Extracellular components influence stem cell polarity by maintaining 
mitotic spindles for asymmetric division, therefore ensure the self-renewal 
capacity of stem cells [49]. The expansion and differentiation of stem cells are 
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strictly regulated by ECM factors. Disruption of this regulating system results 
in uncontrolled expansion, loss of polarity and differentiation and ultimately 
tumor development [50]. The ECM derived from bone marrow stromal cells or 
bone marrow mesenchymal cells was shown to stimulate mesenchymal stem 
cell expansion and prevent stem cell differentiation [51, 52]. The ECM 
expands stem cell populations by activating Erk1/2 and cyclin D1, which are 
responsible for cell-cycle progression and cells’ commitment to S phase. The 
effects of the ECM on survival signaling were postulated to be via integrin 
activation or inhibition of reactive oxygen species (ROS) levels. As stem cell 
expansion has been proved to drive tumor development and recurrence [53], 
the ECM may contribute to tumor development via its effects on stem cell 
populations. Besides regulating stem cell expansion, secreted molecules in the 
ECM and intercellular junctions are required for stem cell differentiation [54]. 
Stem cells grown in ECM conditions similar to brain or bone express neuronal 
or musculoskeletal markers, suggesting that the ECM provides driving forces 
for the differentiation of some stem cell lineages [55]. 
 
Cancer progress and metastasis: 
The ECM also plays crucial roles in cancer progress. Degradation of the 
basement membrane, a physical barrier against cell migration, by matrix-
degrading enzymes leads to migration and invasion of cancer cells to distant 
sites [46]. In fact, changes in ECM structure, such as thickened and linearized 
collagen, are usually observed in tissues with active invading cells or 
angiogenesis [56]. The ECM influences angiogenesis or tumor vasculature due 
to its stimulatory roles in blood vessel formation. In addition, ECM anomalies 
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trigger recruitment of various factors, such as fibroblasts and immune cells, to 
create a tumor microenvironment that favors tumor progression [56]. 
 
Cancer recurrence: 
The ECM drives cancer recurrence by activating tumor cells that are in 
dormant state. Quiescent cancer cells present at distant sites are converted to 
malignant forms when there is a favorable environment. Laminin-5 and 
fibronectin have been shown to trigger that transition process resulting in 
cancer metastasis or recurrence [57]. Details of the important roles of 
fibronectin in tumor recurrence will be reviewed in the following part. 
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1.3. FIBRONECTIN 
1.3.1.  Fibronectin structure 
Fibronectin is a crucial and ubiquitous component of the ECM. 
Fibronectin exists in the fibril structure of the ECM and basement membrane 
to function as ECM scaffold, together with other fibers from collagen or 
elastin. Fibronectin is also present in the interstitial matrix, which interacts 
with both cells and basement membrane [58]. Fibronectin consists of two 
identical glycoprotein molecules connecting via disulfide bonds at the C-
termini, with molecular weight of about 220-250 kDa each. The fibronectin 
monomer contains 3 types of repeating domains, which are types I, II and III, 
and a variable (V) region. There are numerous binding sites in a fibronectin 
molecule for binding with other ECM proteins, such as collagen, laminin, and 
elastin, and for binding with cellular surface via integrin receptors. Fibronectin 
are further modified by proteolysis or incorporation of type III extra domains 
A or B (EDA or EIIIA and EDB or EIIIB respectively) to expose cryptic 
positions for additional binding. [59]  
All human fibronectin isoforms are encoded by one pre-mRNA 
generated from one single gene. The pre-mRNA is alternatively spliced at 
extra domains EDA, EDB or the variable (V) region to generate different 
fibronectin variants [60]. As a result of alterative splicing, there are more than 













Figure 1.5. Fibronectin structure. Fibronectin consists of 2 monomer 
glycoproteins connecting via disulfide bonds. Each monomer contains 
repeated types I, II and III domains, a variable (V) region and alternatively 
splicing domains (A and B). A figure from a chapter by Jielin Xu D.M. et al. 
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1.3.2. Regulation of fibronectin expression 
Fibronectin production in cells is regulated by different factors. Tumor 
necrosis factor alpha (TNF-) stimulates fibronectin expression in coronary 
artery smooth muscle cells by a post-transcriptional mechanism dependent on  
nitric oxide [62, 63]. Basic fibroblast growth factor (bFGF) activates 
phosphatidylinositol phospholipase gamma 2 (PLC2), protein kinase C alpha 
(PKC), c-Src and NFB in osteoblasts, resulting in fibronectin synthesis [64]. 
In rat hepatocytes, the transcription of fibronectin is also regulated by NFB 
by the binding of p65/p65 homodimer to fibronectin promoter [65]. High 
fibronectin expression was observed in the livers of Hepatitis B virus (HBV) 
carriers and co-localized with HBVx antigen (HBVxAg). HBVx Ag was 
shown to control fibronectin expression by transactivating fibronectin 
promoter via NFB and repressing tumor suppressor p53 [66]. 
In some cancer cells, fibronectin gene is regulated by the transcription 
factor early growth response 1 (EGR-1), which plays important roles in 
regulating cell proliferation and differentiation. Overexpression of EGR-1 in 
human glioblastoma cells resulted in high fibronectin expression. EGR-1 
exerted its effect by binding to 2 binding sites between -75 to -52 and -4 to 
+14 of the fibronectin promoter [67]. In melanoma cell lines, EGR-1 was also 
shown to bind to fibronectin promoter upon stimulation by hepatocyte growth 
factor (HGF) via activation of mitogen-activated protein kinase (MAPK). 
Consistenly, overexpression of NGFI-A binding protein (NAB2), the co-
supressor of EGR-1, in melanoma cells reversed the effect of HGF on 
fibronectin expression [68]. 
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Fibronectin expression is also regulated by post-transcriptional 
mechanisms including modification of mRNA stability and translation 
efficiency [69]. The 3’-untranslated region (UTR) in fibronectin mRNA 
consists of putative regulatory elements that play an important role in 
translation of fibronectin. Activation of the regulatory elements resulted in 
enhanced fibronectin mRNA turnover as well as fibronectin translation. Zhou 
et al [69, 70] demonstrated that light chain 3 of microtubule-associated 
proteins 1A/1B (LC3) bound to AU-rich region in UTR of fibronectin mRNA 
and facilitated attachment of ribosomes on fibronectin mRNA in endoplasmic 
reticulum (ER). As a result, LC3 directly augmented translation fibronectin 
mRNA. Taken the association of LC3 with microtubules into account, Zhou et 
al.  [70] additionally showed that microtubules work in tandem with LC3 to 
increase fibronectin translation.  
 
1.3.3. Regulation of fibronectin secretion 
Two main forms of fibronectin exist, including plasma fibronectin in 
blood and cellular fibronectin in cytoplasm of cells. The two forms are 
different in structure and secreted by different origins. Plasma fibronectin is 
secreted by hepatocytes in a soluble form, without the presence of alternative 
splicing domains EDA and EDB. Fibroblasts, epithelial cells and endothelial 
cells are the main sources of cellular fibronectin, which is secreted in soluble 
forms and then converted to insoluble forms by incorporating into the fibril 
structure of the ECM. Unlike plasma fibronectin, cellular fibronectin contains 
alternative splicing  EDA and/or EDB domains [59].  
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As mentioned above, fibroblasts have long been thought to be the main 
source of fibronectin secretion into ECM. However, mounting evidence has 
shown that some cancer cells such as melanoma [71] and hepatoma cells [72] 
also secrete fibronectin for purposes not-fully-understood.  
Information about the secretion process of fibronectin is not abundant in 
literature. Like other secretory vesicles, fibronectin is synthesized in ER, post-
translationally modified while it traffics from ER to Golgi network and finally 
secreted outside. Post-translational modification of fibronectin include 
glycosylation, phosphorylation and sulfation [73] to stabilize fibronectin from 
proteolytic degradation as well as to promote its binding capacity to other 
molecules [74, 75]. As a result, post-translational modification greatly 
contributes to the heterogeneity of fibronectin isoforms. 
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1.3.4. Functions of fibronectin in cell biology 
1.3.4.1. Functions of fibronectin in normal cell biology 
Fibronectin mediates the interactions between the ECM and cells via its 
binding to integrin receptors on the cell surface due to numerous binding 
domains in fibronectin molecule. The fibronectin-regulated interactions 
between the ECM and cells provide downstream signals of integrin pathways 
to promote cellular  proliferation, survival and migration (Figure 1.6) [76].  
 
 
Figure 1.6. Integrin signaling pathways. An adapted figure from a chapter 
by Reiske H.R. (Encyclopedia of Cancer (Second Edition), J.R. Bertino, Editor. 
2002, Academic Press: New York. p. 493-499) [76] 
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Fibronectin interacts with numerous transmembrane integrin receptors. 
It specifically binds to integrin 51, IIb1, 31, v3 via the Arg-Gly-
Asp (RGD)-binding sites. RGR-binding sites are synergized by PHSRN 
peptide sequence at the 10th and 9th type III domains. Fibronectin also binds to 
integrin 41 via EDGIHEL sequence on EDA domain, and binds to 47 via 
LDV sequence on the variable (V) domain [59]. Upon binding to fibronectin, 
the heterodimers of integrin reorganize to expose binding sites for other 
intracellular molecules to bind to and be activated, such as focal adhesion 
kinase (FAK) and phosphoinositol 3 kinase (PI3K), c-Src, protein kinase C 
(PKC) and RhoGTPase family [76].  
Not only does fibronectin affect cellular behavior, it also influences 
several physiological processes such as wound healing and thrombosis. 
Plasma fibronectin exists in circulation in an inactive form inside platelets. 
Once activated by the coagulation cascade following wound response, plasma 
fibronectin is secreted from platelets and deposited into ECM, where it attracts 
and stimulates adherent platelets and fibroblasts. Recruited fibroblasts secrete 
more cellular fibronectin, whilst platelets produce more plasma fibronectin. 
Cellular fibronectin, in turn, attracts more fibroblasts as well as other ECM 
proteins for thrombosis and wound healing processes [77, 78]. 
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1.3.4.2. Functions of fibronectin in tumor biology 
Cancer survival: 
Several isoforms of fibronectin have been detected at high expression 
levels in some malignancies such as lung and colorectal cancers. By binding to 
integrin receptors, fibronectin stimulates numerous signaling pathways that are 
responsible for cancer tumorigenesis, anti-apoptosis and proliferation. The 
signaling pathways regulated by fibronectin-integrin include mitogen-
activated protein kinases (MAPK), GTPase, PI3K/Akt/m-TOR [79-82], which 
have been established as pro-survival signaling pathways. Indeed, inhibition of 
fibronectin-intergrin binding by anti-51 integrin or inhibition of PI3K 
abrogated the effects of fibronectin on cancer survival and anti-apoptosis [83]. 
In suspending culture condition, aggregates of human oral squamous 
carcinoma cells expressed higher fibronectin and integrin 5 receptors, and 
hence survived better than single cells [84]. 
 
Cancer invasion and metastasis: 
It has been shown in ovarian cancer cells that fibronectin binding to 
integrin 51 triggered activation of c-Met in a mechanism independent of 
HGF, followed by stimulation of Src and FAK. The activation of this signaling 
resulted in increased cancer invasion and metastasis both in vitro and in vivo. 
In addition, inhibition of fibronectin-integrin binding by injection of anti-
integrin 5 reversed the effects of fibronectin on invasion and metastasis in a 
mice model [85]. Interestingly, Kaplan et al. [86] have shown in a xenograft 
model that when a primary tumor was established, fibronectin was secreted by 
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stromal cells at the sites where metastasis often appears, followed by 
recruitment of VEGFR1-expressing hematopoietic progenitor cells (HPCs) 
from bone marrow. HPCs traversed through endothelium to the distal sites and 
created a pro-metastatic tumor microenvironment, even before tumor cells 
metastasized to those sites. Barkan et al. [57] observed that when fibronectin 
was produced by dormant mammary cancer cells, the cells left the quiescent 
state and proliferated. Moreover, exogenous fibronectin drove cancer cells 
form dormancy to metastasis. Taken together, these findings emphasize the 
important involvement of fibronectin in cancer invasion and metastasis. 
 
Anoikis resistance: 
Normal epithelial cells, when detached from ECM anchorage, undergo a 
type of anchorage-dependent apoptosis named anoikis. However, cancer cells 
survive anoikis by developing various measures to become anchorage-
independent. Hamster ovary cells survived anoikis condition in serum-
withdrawn culture medium due to fibronectin. Fibronectin exerted the anti-
apoptotic effects by upregulating expression of B-cell lymphoma 2 (Bcl-2) 
independent of FAK [87]. On the other hand, fibronectin was shown to induce 
anoikis resistance in human squamous carcinoma (HSC-3) cells in a FAK-
dependent mechanism [84]. Interaction of fibronectin and intergrin 5 resulted 
in phosphorylation of FAK at tyrosine 397 and suppression of p53, and hence 
protected the cells from anoikis. Anoikis resistance in HSC-3 in the 
suspension condition could be reversed by inhibition of FAK phosphorylation. 
The findings suggest that HSC-3 used fibronectin in ECM or produced by 
other cells to acquire anoikis resistant capacity. Interestingly, fibronectin 
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structure is of crucial importance in regulating cancer cells’ survival in anoikis 
condition. Instead of inducing anoikis resistance, aberrant fibronectin structure 
with non-functional high-affinity heparin-binding domain promotes 
apoptosis of squamous carcinoma cells in a suspension condition. By down-
regulating the expression of integrin 5 receptor, the mutated fibronectin 
suppresses FAK phosphorylation and ERK phosphorylation resulting in 
enhanced anoikis. [88] 
 
Drug resistance: 
Fibronectin stimulated downstream signaling of integrin 1 and changed 
the sensitivity of cancer cells to chemotherapy-induced apoptosis [89], 
suggesting that fibronectin promotes resistance of cancer cells to apoptotic 
reagents. Indeed, several studies have shown that fibronectin protects cancer 
cells from chemo-reagents. Xenograft-derived endothelial cells, when cultured 
on fibronectin, became resistant to DNA-breakage induced by etoposide [90]. 
Fibroblast-produced fibronectin protected colon cancer cells form apoptosis 
induced by etoposide and camptothecin [91]. Consistently, when fibronectin-
integrin connection was inhibited by 51 antibodies, the cisplastin-resistant 
ovarian cancer cells became more sensitive to apoptotic-induced conditions 
such as anchorage-independence or serum derivation [92]. 
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1.4. INTERACTION BETWEEN ACTIN CYTOSKELETON 
AND EXTRACELLULAR MATRIX REMODELING 
1.4.1. The role of actin cytoskeleton in ECM-dependent apoptosis 
Abnormal cytoskeletal remodeling and anoikis resistance are two 
common features of cancer cells. Normal epithelial cells require attachment to 
the ECM for survival and proliferation. When normal cells are detached from 
the ECM, they undergo a process called anoikis, which is an ECM-anchorage-
dependent cell death. Anchorage-independent survival and anoikis-resistance 
are special abilities that cancer cells develop to allow them to survive without 
ECM attachment to colonize at distant metastatic sites. [93] 
Actin cytoskeleton is one of the important factors that regulate anoikis-
resistance in cancer cells. The stress fiber-stimulating factor tropomyosin 
isoform-1 (TM1), which stabilizes actin filaments, was shown to stimulate 
anoikis in breast cancer cells MDA-MB-231. Consistently, disruption of actin 
filaments by latrunculin A rescued breast cancer cells from anoikis induced by 
TM1 [94]. Although the role of actin cytoskeleton in regulating anoikis in 
cancer cells is established, the mechanisms underlying this effect still need to 
be elucidated.  
 
1.4.2. Direct interaction between actin cytoskeleton and the ECM 
Actin cytoskeletal reorganization plays important roles in a number of 
cell activities including maintaining cell shape, facilitating cell motility and 
involving in cellular reactions to external environment [95]. Fibrils of 
fibronectin are formed in the infolding area of cell surfaces, which is formed 
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by fusion of secretory vesicles and plasma membrane. Actin filaments 
mechanically link with fibronectin and other ECM proteins via specific 
surface receptors of the integrin family. This connection allows the 
transmission of signals and mechanical forces from the ECM to the actin 
cytoskeleton and vice versa [96]. Indeed, actin and myosin are able to pull on 
extracellular fibronectin via integrin to expose binding sites for fibronectin or 
other ECM proteins. Thus, the cytoskeleton indirectly stimulates the assembly 
of fibronectin and other ECM proteins into fibrils. In addition, the 
cytoskeleton regulates the orientation of these fibrils. When organization of 
actin filaments is disturbed, the fibrils are disconnected from the surface, 
releasing cells from interactions with the ECM. This process often happens 
when cells undergo mitosis in normal conditions [43] or in some malignant 
processes such as anchorage-independent survival and dissemination of cancer 
cells. Therefore, by regulating actin reorganization, actin-binding proteins 
such as gelsolin pose importance roles in the interactions between the ECM 
and cellular behavior. 
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1.5. RATIONALE AND OBJECTIVES OF THE STUDY 
The interaction between cancer cells and the ECM has a special position 
in tumor progression. The ECM serves as a platform for cancer cell anchorage, 
proliferation, survival and migration. In return, cancer cells are able to 
remodel the ECM to facilitate their survival, migration and invasion. Cancer 
cells exert these effects by degrading some ECM proteins and/or secreting 
some other components of the ECM. ECM-independent survival or anoikis 
resistance is a special way that cancer cells develop to escape apoptosis and 
cell death in ECM detachment conditions, which normally happen during 
cancer metastasis. Actin cytoskeleton remodeling is an important factor that 
regulates anoikis resistance in cancer cells. As disruption of actin cytoskeleton 
has been shown to induce enhanced anoikis resistance in cancer cells, it is 
possible that actin-severing proteins, such as gelsolin, may exert similar 
effects on cancer survival in anoikis conditions. In addition, as mentioned 
previously, the actin cytoskeleton and gelsolin may affect the secretion of 
ECM proteins. Moreover, gelsolin has been shown to regulate transcription of 
various genes by modulating their transcription factors or transcription co-
activators. Interestingly, fibronectin has binding sites for plasma gelsolin [97, 
98] suggesting a direct connection between the two proteins for as yet 
unknown cellular functions. Taken together, actin-binding proteins in general 
and gelsolin in particular probably play a role in regulating fibronectin 
secretion and expression. Given that fibronectin is a known promoter of 
anoikis resistance in cancer cells, it is possible that gelsolin contribute to 
anoikis resistance via its regulation of fibronectin secretion and expression and 
ECM reorganization. 
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In this study, we postulate that gelsolin affects anoikis resistance and 
cancer cell survival, and gelsolin exerts the effects by regulating fibronectin 
expression and secretion. In order to elucidate the hypothesis, we examine 
whether gelsolin modulates cancer cell survival in an anoikis condition by 
regulating fibronectin secretion. We also investigate the influence of gelsolin 
in the expression and secretion of fibronectin in colorectal cancer cell lines. 
We further explore the mechanisms by which gelsolin regulates fibronectin 




OBJECTIVES OF THE STUDY 
The main objectives of this study are: 
1. To investigate whether gelsolin influences colon cancer survival by 
regulating fibronectin expression and secretion 
2. To explore the mechanisms by which gelsolin regulates fibronectin 
expression and secretion in colon cancer. 









MATERIALS AND METHODS 
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2.1. MATERIALS 
2.1.1. Chemicals and reagents 
1st Base  
siRNA against gelsolin, biotechnology grade water (Buf1180); Tris-HCl 
(B10-1500), 10% SDS (Buf 2051) 
Abcam 
Mouse monoclonal anti-gelsolin (ab11081) (1:1000 dilution); Rabbit 
polyclonal anti-fibronectin antibody (ab2413) (1:400 dilution). 
Ambion 
Silencer FN1 siRNA (4392421) 
Applied Biosystems 
Taqman PCR primers for Gelsolin (Hs00609275_m1); FN1 
(Hs01549976_m1); EGR-1 (Hs 00152928_m1) and GAPDH 
(Hs99999905_m1). 
Bio-Rad 
Protein assay dye reagent (500-0006); Blotting-grade blocker (170-
6404). 
Cell Signaling Technology  
Phospho-Akt (Ser473) Antibody #9271 (1:1000 dilution); Akt1 
(C73H10) Rabbit mAb #2938 (1:1000 dilution). 
Gibco 
Geneticin G418 (10131-027); Opti-MEM (31985); Penecillin-
Streptomycin (10,000 U/mL) (15140-122). 
 





Fetal bovine serum (SV30160.03) 
Invitrogen 
Lipofectamine™ RNAiMAX transfection reagent (13778150); 
Lipofectamine™ 2000 (11668-019); Stealth RNAi™ siRNA Negative 
Control Med GC Duplex (12935-112). 
PAA Laboratories 
Trypsin EDTA (L11-003) 
Promega 
Dual-Luciferase® Reporter Assay System (E1910); ImProm-II Reverse 
Transcription System (A3800). 
Qiagen 
Cignal EGR1 Reporter (luc) Kit (CCS-8021L); RNeasy Mini Kit (250) 
(74106). 
QREC 
Potassium chloride (KCl) (7447407) 
Roche 
Cell proliferation ELISA, BrdU kit (colorimetric) (11647229001); 
Complete Protease inhibitor cocktail tablets (05-872-988-001);  
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Phosphatase inhibitor cocktail (04-906-837-001); Annexin-V-FLUOS 
Staining Kit (11 858 777 001). 
Santa Cruz Biotechnologies 
Mouse monoclonal anti-GAPDH (sc-32233); Goat anti-rabbit IgG  
conjugated with HRP (sc-2004); Goat anti-mouse IgG conjugated with 
HRP (sc-2005). 
Sigma Aldrich 
Dimethylsulfoxide (DMSO) (D2650); Triton X-100 (T8787); McCoy’s 
5A modified medium (M4892); RPMI 1640 (R4130); Sodium 
deoxycholate (D6750); Sodium bicarbonate (S6297); Bovine serum 
albumin (A9418); Trypan blue dye (72-57-1); Ammonium per sulfate 
(A3678); Hepatocyte growth factor (H9661-5UG); Propidium iodide 
(P4170); BAY 11-7085 (B5681); Tumor necrosis factor- human 
(T0157). 
Thermo Scientific 
Super signal, West Dura, extended duration substrate (34076); Stripping 
buffer (21059); LDS Sample Buffer; Non-Reducing (4X) (84788); 
TEMED (Tetramethylethylenediamine) (17919); RNase A, DNA and 
protease-free (EN0531). 
Vivantis 
Tris-Base (PR0612); 10X PBS (PB0344). 
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2.1.2. Cell lines  
HCT116, RKO and DLD-1 are human colon cancer cell lines obtained either 
from the laboratories of Prof. Shing Chuan Hooi or Dr Richie Soong. E1 cells, 
the in vivo-derived metastatic HCT116 cells, were obtained from Prof. Shing 
Chuan Hooi.    
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2.2. METHODS 
2.2.1. Cell culture 
HCT116 and E1 cells were cultured in McCoy’s 5A modified medium 
(Sigma-Aldrich); DLD-1 and RKO were cultured in RPMI 1640 (Sigma-
Aldrich). Serum-free media were media without serum but supplemented with 
1% Penicillin-Streptomycin (Gibco). Complete media contained 10% fetal 
bovine serum (FBS) (Hyclone) and 1% Penicillin-Streptomycin.  Stable 
transfected HCT 116 cell lines (gelsolin-overexpressing cell clones C1 and C8 
and vector control cells) were cultured in McCoy’s 5A medium supplemented 
with 500μg/mL Geneticin G418 (Gibco). All cell lines were grown at 37oC in 
a humidified incubator supplemented with 5% CO2. 
 
2.2.2. DNA stable transfection 
Stable overexpression of gelsolin in HCT 116 cells was described 
previously [34]. Gelsolin-encoding plasmids were generated by insertion of 
human cytoplasmic gelsolin cDNA into pIRES2-EGFP vectors (BD 
Biosciences Clontech). HCT 116 cells were transfected with gelsolin-encoding 
plasmids using FuGENE 6 (Promega) and selected using 500µg/ml G418 
(Gibco). Vector control cells were generated by transfection of empty 
pIRES2-EGFP vector into HCT 116 cells. Transfected cells were selected by 
green fluorescence using Fluorescence Activated Cell Sorting (BD 
FACSCalibur) including clones C1 and C8 as gelsolin-overexpressing cells 
and V4 as vector control cells. 
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2.2.3. siRNA transfection 
The following siRNA duplex oligoribonucleotide sequences (Invitrogen) 
were used for silencing expression of the gelsolin gene: 
Oligo 1: UCUUGAAGAACUGCUUGAACAGUGG 
Oligo 3: AAACGUCCAAUCUUGUUGGAGCAGG  
Fibronectin siRNA for knocking down fibronectin was a pre-designed 
siRNA sequence against the FN1 gene obtained from Ambion. 
For siRNA transfection, cells were cultured in 6-well plates at the density 
of 2.5x106 cells/well in complete McCoy’s 5A medium.  The complexes of 
siRNA and Lipofectamine RNAiMAX transfection reagent (Invitrogen) were 
prepared by mixing a desired amount of 10nM or 20nM siRNA with 
Lipofectamine RNAiMAX in Opti-MEM reduced serum media (Gibco) and 
incubated at room temperature for 15 minutes. The complexes were then 
added to the cell culture in a drop-wise manner and incubated for four hours at 
37ºC in an incubator.  After that transfection media were replaced with 
complete media. Non-targeting siRNA control with medium GC content 
(Invitrogen) was used as a negative control for siRNA transfection. 
 
2.2.4. Protein assay 
Protein concentration was determined using the Bio-Rad protein dye 
reagent (Bio-Rad) with different concentrations of bovine serum albumin 
(BSA) (Sigma-Aldrich) as standards.  One part of the dye reagent was diluted 
with four parts of water and filtered.  10µL of protein samples were added into 
96-well plate with 200µL of 1X Bio-Rad protein dye reagents at room 
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temperature for 5 minutes.  Absorbance was measured at 595nm using a 
microplate reader. 
 
2.2.5. Western blot 
Cell lysate preparation 
Cells were harvested by trypsinisation for 5 minutes and then washed 
with 1X PBS and centrifuged. Cell pellets were lysed by 
radioimmunoprecipitation assay (RIPA) buffer (Sigma Aldrich) supplemented 
with protease inhibitors (Roche), vortexed, put on ice for 15 minutes and 
microcentrifuged at 10,000g for 10 minuties at 4ºC.  The supernatants were 
collected in pre-chilled tubes.  Protein concentration was determined using 
Bradford Protein Assay described above.  In general, 25-40g of extracted 
proteins and 20-30l of culture supernatants were loaded on gels to measure 
the expression and secretion of protetins respectively. The exact amounts of 
proteins were stated in specific experiments. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)  
The resolving gels used in the study (8 and 10%) were prepared with 30% 
bis – acrylamide, 1.5M Tris HCl pH 8.8, 10% SDS, ammonium persulphate 
(APS) and  N, N, N’, N’- tetramethyl – ethylenediamine (TEMED). 5% 
stacking gel was prepared with 30% bis - acrylamide, 1.0M Tris – HCl pH 6.8, 
10% SDS (w/v), and polymerised with ammonium per sulfate (Sigma-Aldrich) 
and TEMED (Thermo Scientific).  Protein samples were diluted with LDS 
sample loading buffer (Thermo) supplemented with 2-mercaptoethanol (Bio-
Rad), and were heated at 95ºC for 5 min before loading into the gels.  Equal 
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total protein amount of samples were loaded into each well for Western blot 
analysis. Housekeeping protein, GAPDH were used to as loading control. 
Samples were run at 80mV for 10 minutes and 150mV for 60-90 minutes 
depending on sizes of the proteins of interest. After that, SDS – PAGE 
resolved proteins were transferred onto activated polyvinylidene difluoride 
(PVDF) membrane, which had been activated by dipping in 100% methanol 
for 15 seconds, water for 2 minutes and then transfer buffer. Electroblotting 
was conducted at 350mA for 1 hour at 4ºC.   
Immunodetection 
After transfer, PVDF membrane was blocked with 5% w/v non-fat milk 
(Bio-Rad) in 1X TBST (20mM Tris – HCl, pH 7.6, 137mM NaCl, 0.1% 
Tween 20) for 1 hour at room temperature.  The membrane was then incubated 
with primary antibodies (diluted in 5% milk w/v in 1X TBST or 5% BSA w/v 
in 1X TBST) and incubated overnight at 4ºC with gentle shaking.  Unbound 
primary antibodies were washed off with 1X TBST (repeated 3 times, 10 
minutes each with vigorous shaking).  After that, the membrane was incubated 
with the respective horse radish peroxidase- conjugated secondary antibodies 
in 5% milk with gentle shaking for 1 hour at room temperature.  Unbound 
secondary antibodies were again washed off with 1x TBST (repeated 3 times, 
10 minutes each with shaking).  The resulting immunocomplexes formed were 
detected using chemiluminescence substrate (Thermo Scientific, West Dura, 
Super signal extended duration substrate).  For re-probing of the same 
membrane for different proteins, the membrane was incubated with stripping 
buffer (Thermo Scientific) for 15 minutes at room temperature.  Membranes 
were rinsed once with 1X TBST for 15 minutes with agitation at room 
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temperature.  Stripped membranes were then re-probed with the respective 
primary and secondary antibodies. 
 
2.2.6. Real-time PCR 
RNA Extraction 
Total RNA was isolated from cells using RNeasy Mini Kit (Qiagen) 
following the manufacturer’s instructions.  Samples were lysed and 
homogenised by passing through a 21-gauge needle ten times.  Ethanol was 
added in a 1:1 ratio to provide ideal binding conditions before the lysates were 
loaded onto the silica membrane columns.  The samples in columns were 
washed a few times using washing buffer to remove contaminants.  RNA was 
then eluted in 30-50μl of RNase-free water.  RNA concentration and quality 
was determined using NanoDrop ND-1000 spectrophotometer.  All RNA 
samples were stored at -80oC before cDNA synthesis. 
cDNA sysnthesis 
6µg of total RNA was converted to cDNA per 20μL reaction using 
ImProm-II Reverse Transcription System reagents (Promega).  Oligo(dT) 
primer (2μg RNA in 1μL Oligo (dt)) was added to RNA in nuclease-free water.  
The reaction mix was heated at 70oC for 5 minutes for target RNA and primer 
combination.  This reaction mix was immediately chilled on ice for 5 minutes 
before adding reverse transcription reaction mix (ImProm-II5X Reaction 
Buffer, 3mM MgCl2, 0.5mM dNTP Mix, 20 units of Recombinant RNasein 
Ribonuclease Inhibitor and ImProm-II Reverse Transcriptase).  The reaction 
mix was then incubated at 25oC for 5 minutes, 42oC for 50 minutes for 
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annealing and extension step respectively.  A no-template (RNA) control was 
included.  The cDNAs were stored at -20oC until real-time PCR. 
 
Real-Time PCR 
Real-time PCR was carried out on the ABI 7500 Fast Real-time PCR 
system.  cDNA was added to a custom Taqman Gene Expression Assay 
comprising a primer and Taqman probe, and combined with Taqman 
Universal PCR Master Mix (Applied Biosystems) according to manufacturer’s 
instructions.  PCR cylcles include one cycle at 95oC for 10 minutes, followed 
by 40 cycles of denaturation at 95oC for 15 seconds and annealing extension at 
60oC for 1 minute. GAPDH primer was included as an internal control. 
 
2.2.7. Immunofluorescence microscopy 
Cells were plated onto a cover slip at a density of 2.5x104 in a 24-well 
plate in complete media for 24h. After that cells were fixed with 4% 
paraformaldehyde in 1X PBS for 15 minutes at room temperature and washed 
with 1X PBS.  Cells were permeabilised with 0.1% Triton X-100 in 1X PBS 
for 10min, and then blocked with 20% goat serum in PBS for 1h at room 
temperature. Cells were then incubated with fibronectin antibodies (Abcam) 
(1:100 dilution  in 1% BSA in PBS) at 40C overnight in a humidifier chamber. 
Cells were washed three times with 1X PBS and incubated with secondary 
antibodies (1:400 dilution in 1% BSA in PBS) for 1 hour at room temperature 
followed by washing three times.  The coverslips were mounted on a glass 
slide with VECTASHIELD® mounting medium containing nuclear counter 
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stain DAPI (Vector Laboratories).  Samples were imaged with 100X oil 
immersion using Olympus Fluoview FV1000.  The images were processed 
using Olympus Fluoview Viewer (Ver 2.0). 
2.2.8. Anoikis model for studies of apoptosis and cell death 
Cells were cultured in attachment plates in complete media before being 
trypsinized and collected. Cells were then counted and put into non-
attachment plates (Corning Cat#3471) in serum-free media for 24 h for 
apoptosis study or cell death study. 
 
 
2.2.9. Cell death analysis by flow cytometry 
Cultured cells were collected for centrifugation at 405g in 5 min. Pellets 
were collected and re-suspended in 1X PBS. Cell pellets were then fixed with 
70% ethanol while vortexing to avoid clumping. Suspensions were then kept 
at 4oC overnight. After that cell pellets were centrifuged, washed with 1X PBS 
and re-suspended in propidium iodide (Sigma Aldrich) (200µg/mL DNase-
free Rnase A, 20µg/mL propidium iodide in 0.1% (w/v) Triton X-100 in PBS) 
for 30 min at room temperature. Cells were filtered and subjected to flow 
cytometry using Becton Dickinson FACScalibur with excitation wavelength 
288 nm and emission wavelength 610 nm. Data was analyzed using CellQuest 
Pro or WinMDI 2.9 software. 
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2.2.10. Apoptotic analysis by flow cytometry 
Cultured cells were collected for centrifugation at 405g in 5 min. Pellets 
were collected and washed twice with 1X PBS. After that cell pellets were 
centrifuged and incubated in Annexin-V FLUOS labeling solution (Roche) for 
15 min at room temperature. Cells were then diluted with incubation buffer, 
filtered and analyzed Becton Dickinson FACScalibur using 488 nm excitation 
and a 515 nm bandpass filter for fluorescein detection. Data was analyzed 
using CellQuest Pro or WinMDI 2.9 software. 
 
2.2.11. Luciferase reporter assay 
Transcriptional activity of EGR-1 and NFB was measured by dual-
luciferase reporter assay as per manufacturer’s instructions (Qiagen). For 
testing the effects of gelsolin overexpression, transcription factor (EGR-1 or 
NFB)-responsive reporter, negative control, and positive control constructs 
were mixed with the transfection reagent Lipofectamine 2000 (Invitrogen) and 
transfected to HCT 116 cells, vector control cells and gelsolin-overexpressing 
cells. For testing the effects of gelsolin knock-down, EGR-1 or NFB-
responsive reporter, negative control, and positive control constructs were 
diluted and mixed with diluted gelsolin siRNA or control siRNA (Invitrogen). 
The diluted nucleic acids were then mixed with Lipofectamine 2000 
(Invitrogen) and transfected to cells. After 24h, culture media was replaced 
with serum-free media and incubated for another 24h. Following transfection, 
cells were harvested into cell lysis buffer (Promega) and luciferase activity 
was measured using the Dual-Luciferase Assay System (Promega) using a 
 48   
 
Varioskan Flash Multimode Reader (Thermo Scientific). Relative 
transcriptional activity was calculated by the following fomula: 
 
At least 3 independent transfections were performed in duplicate for each of 
the conditions tested with each reporter assay. 
 
2.2.12. Statistical analysis 
All statistical analyses were performed using Mann-Whitney U test. 
Differences between sample means were considered statistically significant 
with p < 0.05.  
  











GELSOLIN PROMOTES CANCER CELL SURVIVAL 
BY UPREGULATING 
FIBRONECTIN EXPRESSION AND SECRETION 
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3.1. BACKGROUND 
Gelsolin has been associated with increased cancer cell survival, 
migration and invasion. Several investigations have shown that overexpression 
of gelsolin enhanced cell survival, migration and invasion, whilst loss of 
gelsolin resulted in decreased motility and invasion capacity. Gelsolin was 
considered as a tumor suppressor in some studies on primary tumors. However 
it was found highly expressed in invasive and metastatic cancers such as 
urothelial carcinoma, EGFR-positive breast cancer, and non-small cell lung 
cancer [26, 99-104]. These findings suggest that gelsolin may have different 
roles in different stages of cancer.  
We have recently shown that overexpression of gelsolin enhanced 
invasion of colon cancer cells by increasing the expression and secretion of 
urokinase plasminogen activator (uPA), a potent matrix-degrading enzyme. 
We also observed increased gelsolin expression at the invasive border of 
metastatic colorectal tumors [105]. These data show an important contribution 
of gelsolin in remodeling the tumor ECM to promote tumor progression. 
Among ECM proteins, fibronectin stands a special position in tumor 
biology as it has pivotal roles in cancer survival, proliferation, migration and 
invasion. High fibronectin expression was reported in several cancers. 
Fibronectin was identified to be one of the top 10 genes that were expressed at 
high levels in human colorectal cancer tissues compared to normal lesions 
[106].  High fibronectin expression was also observed in breast cancer tissues 
at advanced stages compared to earlier stages [107]. EDA isoform of 
fibronectin was found to be highly expressed in metastatic melanoma tissues 
compared to benign lesions [108]. Although fibronectin has long been thought 
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to be secreted by stromal cells like fibroblasts, mounting evidence has shown 
that cancer cells such as melanoma and hepatoma cells are also important 
sources of fibronectin [68, 109]. Interestingly, the presence of fibronectin was 
detected along migratory trails of cancer cells, suggesting that fibronectin was 
secreted when cancer cells migrate [110]. Fibronectin bound to integrin 
receptors on cell surface and triggered various signaling pathways such as 
MAPK, GTPase, PI3K/Akt/m-TOR to favor cell survival [79-82]. Inhibition 
of the interaction between fibronectin and integrin receptors using anti-
integrin 5 antibodies reversed the anti-apoptosis and pro-survival effects of 
fibronectin [83]. Collectively, these findings emphasize the stimulatory 
involvement of fibronectin in cancer progression. 
However, despite the important roles of fibronectin in cell biology in 
general and in tumor biology in particular, information about the secretion of 
fibronectin by cancer cells is still poorly understood. Moreover, it needs to be 
elucidated how the expression and secretion of fibronectin is regulated in 
cancer cells. In this chapter, we investigated the roles of gelsolin in the 
regulation of fibronectin expression and secretion in colorectal cancer cells. 
We explored the roles of gelsolin in cancer cell survival and found that 
gelsolin promoted survival of cancer cells under suspension conditions. Our 
findings indicated that gelsolin promoted cancer survival by enhancing 
fibronectin expression and secretion in colorectal cancer cell lines.  
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3.2. OBJECTIVES 
1) To establish the roles of gelsolin in regulating fibronectin expression and 
secretion in colorectal cancer 
2) To examine whether gelsolin regulates fibronectin expression and secretion 
to promote cancer cell survival.  
 
Study model: 
To investigate the roles of gelsolin in regulating fibronectin expression 
and secretion,  we modulated gelsolin levels using gain-of-function and loss-
of-function models in HCT 116, as described previously by our research group 
[34]. The gain-of-function model of gelsolin was achieved by stably 
overexpressing a plasmid encoding the cytoplasmic gelsolin sequence in HCT 
116 colorectal cancer cells. The loss-of-function model was established by 
siRNA knock-down of gelsolin in HCT 116, RKO, DLD-1 colorectal cancer 
cells. We also used these models to investigate the effects of gelsolin on 
apoptosis and cell death in HCT 116 cells. The apoptosis and cell death studies 
were performed using an anoikis model, which was adapted from a study by 
Lee et al. [111]. Briefly, HCT 116 cells were cultured in suspension 
conditions in non-attachment plates with serum-free media. The anchorage-
inhibition due to the suspension culture as well as the absence of serum in 
media induced apoptosis and cell death in HCT 116 cells. 
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3.3. RESULTS 
3.3.1.  Expression and secretion of fibronectin correlate with gelsolin 
expression in colorectal cancer cells 
Previous studies have shown that fibronectin expression and secretion 
were detected in melanoma and hepatocellular carcinoma cells [71, 72]. We 
investigated whether fibronectin was also expressed and secreted in colorectal 
cancer cell lines HCT 116, E1, DLD-1 and RKO. As described previously, E1 
was the in vivo derivation of HCT 116 cells in liver metastasis by repeated 
injection of HCT 116 cells into the spleen of nude mice [34]. Colorectal 
cancer cells were cultured in serum-free media for 48h. Supernatants and cells 
were collected for analysis of gelsolin and fibronectin. Western blot results 
showed that fibronectin was secreted and expressed in colorectal cancer cell 
lines HCT 116, E1, RKO and DLD-1. Fibronectin expression and secretion 
were higher in HCT 116 and E1 cells than that in RKO and DLD-1 cells. 
Moreover, fibronectin expression and secretion correlated with gelsolin levels 
in the cell lines. (Figure 3.1A) 
We choose HCT 116 cells, which exhibited relatively high fibronectin 
expression and secretion, for further investigation. HCT 116 cells were 
cultured in serum-free media. Supernatants and cultured cells were collected 
for Western blot analysis after 24h or 48h. Figure 3.1B shows that fibronectin 
was detected intracellularly and increasing amounts of fibronectin were 
detected in the supernatants after 24h and 48h of culture. To confirm that 
fibronectin detected in the supernatants of HCT 116 cell culture was not 
resulted from disruption of cell membrane integrity, but it was secreted by 
HCT 116 cells, we treated the cells with brefeldin A, an inhibitor of secretory 
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pathways. Brefeldin A was reported to induce collapse of Golgi stacks 
resulting in inhibition of secretion of all secretory vesicles [112]. Figure 3.1C 
shows that fibronectin in the culture media of HCT 116 cells was detected at 
lower levels when the cells were treated with brefeldin A, coinciding with 
higher expression of intracellular fibronectin. These findings confirmed that 
fibronectin detected in the supernatants of HCT 116 cell culture was secreted 
by HCT 116 cells. This secretion was attenuated by treatment with brefeldin A, 
resulting in intracellular fibronectin trapped inside the cells. 
  
















Figure 3.1. Fibronectin expression and secretion in colorectal cancer 
cells. (A) Colorectal cancer cell lines HCT 116, E1, DLD-1, RKO were 
cultured in serum-free media for 48h. After that, 15l of supernatants and 
25g of extracted proteins were analyzed by Western blot to measure 
secreted fibronectin and intracellular proteins respectively. A representative 
Western blot (upper) and quantitative analysis of Western blots (lower); data 
shown are mean ± SD of three independent experiments; p-value<0.01, *p-
value<0.05 (Mann-Whitney U test) compared to HCT 116 in the same group. 
(B) HCT 116 cells were cultured in serum-free media for 24 and 48h. 20l of 
supernatants and 25g of extracted proteins were analyzed by Western blot 
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to measure secreted fibronectin and intracellular proteins respectively. A 
representative Western blot (upper) and quantitative analysis of Western 
blots (lower); data shown are mean ± SD of three independent experiments. 
*p-value<0.05 (Mann-Whitney U test) compared to 0h in the same group.  
(C) HCT 116 cells were cultured in serum-free media in the presence of 0, 50, 
75ng/ml brefeldin A for 12h. 30l of supernatants and 25g of extracted 
proteins were analyzed by Western blot to measure secreted fibronectin and 
intracellular fibronectin respectively. A representative Western blot (upper) 
and quantitative analysis of Western blots (lower); data shown are mean ± 
SD of three independent experiments. *p-value <0.05 (Mann-Whitney U 
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3.3.2.  Models of gelsolin overexpression and siRNA knock-down used to 
investigate the effects of gelsolin on fibronectin expression and secretion 
Previous data showed the correlation of gelsolin expression and the 
expression and secretion of fibronectin. In order to investigate the effects of 
gelsolin on fibronectin, we modulated gelsolin levels by gain-of-function and 
loss-of-function models. We overexpressed gelsolin in HCT 116 cells by 
stable transfection with the pIRES2-EGFP plasmid encoding human 
cytoplasmic gelsolin cDNA as reported previously (Appendix I) [34]. Control 
cells were generated by stable transfection with empty pIRES2-EGFP plasmid. 
Gelsolin in HCT 116 cells was knocked down by transfection with either of 
two siRNA sequences, oligo 1 or oligo 3. Control cells were transfected with 
non-targeting siRNA control. Our results showed that gelsolin-overexpressing 
cells (C1 and C8) expressed higher levels of gelsolin compared to vector 
control cells and wild-type HCT 116 cells (Figure 3.2A), whilst cells with 
knock down using siRNA (oligo 1 or oligo 3) against gelsolin expressed lower 
gelsolin compared to control cells (Figure 3.2B). 
  





Figure 3.2. Modulation of gelsolin expression in HCT 116 cells. (A) 
Western blots of geloslin overexpression. HCT116 cells were stably 
transfected with pIRES2-EGFP plasmid encoding human cytoplasmic gelsolin 
cDNA. Two clones C1 and C8 were chosen for investigation. Vector controls 
cells were transfected with empty pIRES2-EGFP plasmid. 25g of extracted 
proteins were analyzed by Western blot. (B) Western blots of gelsolin knock-
down at 72h after transfection. HCT 116 cells were transfected with 10nM 
either of two siRNA sequences against gelsolin, oligo 1 or oligo 3, whilst 
siRNA control cells were transfected with non-targeting negative control 
siRNA for 72h. 25g of extracted proteins were analyzed by Western blot to 
measure intracellular gelsolin expression. 
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3.3.3.  Gelsolin upregulates fibronectin expression and secretion 
Our previous results demonstrated that fibronectin was secreted by HCT 
116 cells. In this part of the study, we modulated levels of gelsolin to 
examine the effects of gelsolin on fibronectin expression and secretion.  
Wild-type HCT 116 cells, gelsolin-overexpressing cells (C1 and C8) and 
vector control cells (V4) were cultured in serum-free media. Supernatants 
and cultured cells were collected for real-time PCR, Western blot and 
immunofluorescence microscopy.  
As shown in Figure 3.3, overexpression of gelsolin induced an increase 
in fibronectin expression in both mRNA (Figure 3.3A) and proteins levels 
(Figure 3.3B&C). Moreover, fibronectin secretion was also enhanced by 
gelsolin overexpression compared to control cells (Figure 3.3B).  
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Figure 3.3. Gelsolin overexpression upregulates fibronectin expression 
and secretion by HCT 116 cells.  
(A) HCT 116 cells, gelsolin-overexpressing cells (C1 and C8) and control 
cells (V4) were cultured in serum-free media for 24h. Cultured cells were 
collected for real-time PCR analysis. Data shown are mean± SD of at least 
three independent experiments.  *p-value <0.05; **p-value <0.01 (Mann-
Whitney U test).  
(B & C) HCT 116 cells, gelsolin-overexpressing cells (C1 and C8) and vector 
control cells (V4) were cultured in serum-free media for 48h. (B) 20l of 
supernatants and 25g of extracted proteins were analyzed by Western blot to 
measure secreted fibronectin and intracellular proteins respectively. A 
representative Western blot (upper) and quantitative analysis of Western blots 
(lower); data shown are mean ± SD of three independent experiments; *p-
value<0.05 (Mann-Whitney U test) compared to HCT 116 in the same group.  
(C) Cells were collected, fixed, permeabilized and incubated with fibronectin 
antibodies and then Alexa Fluor 568-conjugated secondary antibodies (red).  
Nuclei were counter-stained with DAPI (blue). 
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In order to investigate the effects of gelsolin knock-down on fibronectin, 
HCT 116 cells were transfected with gelsolin siRNA (oligo 1 or oligo 3) or 
control siRNA for 72h, and re-cultured in serum-free media. Cultured cells 
and supernatants were collected for real-time PCR, Western blot and 
immunofluorescence microscopy.  
As shown in figure 3.4, knock-down of gelsolin induced a decrease in 
fibronectin expression in both mRNA (Figure 3.4A) and proteins levels 
(Figure 3.4B&C). Moreover, fibronectin secretion was also attenuated by 
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Figure 3.4. Gelsolin knock-down attenuates fibronectin expression and 
secretion in HCT 116 cells. HCT 116 cells were transfected with gelsolin 
siRNA (oligo 1 or oligo 3) or control siRNA for 72h and then re-plated in 
serum-free media.  
(A) Cells were cultured in serum-free media for 24h, and then cell pellets were 
collected for real-time PCR analysis. Data shown are mean± SD of at least 
three independent experiments.  *p-value <0.05; **p-value <0.01 (Mann-
Whitney U test). 
(B & C) Cells were cultured in serum-free media for 48h. (B) After that 20l 
of supernatants and 25g of extracted proteins were analyzed by Western blot 
to measure secreted fibronectin and intracellular proteins respectively. A 
representative Western blot (upper) and quantitative analysis of Western blots 
(lower); data shown are mean ± SD of three independent experiments; *p-
value<0.05 (Mann-Whitney U test) compared to control siRNA in the same 
group.  (C) Cultured cells were collected, fixed, permeabilized and incubated 
with fibronectin antibodies and then with Alexa Fluor 488-conjugated 
secondary antibodies (green). Cells were then stained with gelsolin antibodies 
and Alexa Fluor 568-conjugated secondary antibodies (red).  Nuclei were 
counter-stained with DAPI (blue).  
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3.3.4.  Gelsolin protects cancer cells from cell death in anoikis model 
We investigated the protective effects of gelsolin on cancer cell survival 
using a model of anoikis, in which HCT 116 cells were cultured in non-
attachment plates in serum-free media as illustrated below.  
 
Anoikis model of apoptosis and cell death 
 
After 24h of culture, cells were then collected for fixing with ethanol 
and staining with propidium iodide and subjected to flow cytometry for cell 
cycle analysis. Cell death was determined by measuring percentages of subG1 
populations. Our results showed that when cultured in the anoikis condition, 
gelsolin-overexpressing cells (C1 and C8) exhibited less cell death compared 
to vector control cells (Figure 3.5). When HCT 116 cells were treated with 
gelsolin siRNA to knock down gelsolin, cell death was significantly increased 
compared to cells treated with control siRNA (Figure 3.6). These data suggest 
that gelsolin protects cancer cells against anchorage-dependent cell death.  
  











Figure 3.5. Gelsolin overexpression protects HCT 116 cells from cell 
death in anoikis model (flow cytometric analysis of propidium iodide 
staining). HCT 116, vector control (V4) and gelsolin-overexpressing cells 
(C1 and C8) were cultured in non-attachment plates at density of 2x106 
cells/24-well  in serum-free media for 48h. After that, cells were collected, 
fixed with ethanol, stained with propidium iodide and then subjected to cell 
cycle analysis by flow cytometry. (A) Representative results of cell cycle 
analysis of HCT116, vector control  cells and gelsolin-overexpressing cells 
(labeled as Gelsolin O/E cells (C1) and Gelsolin O/E cells (C8) in the flow 
histograms). Percentages of subG1 populations are indicated. (B) Cell death 
in HCT 116, vector control cells and gelsolin-overexpressing cells (C1 and 
C8) measured by percentages of subG1 population in cell cycle analysis. 
Data shown are mean± SD of three independent experiments.  **p-value 
<0.01 (Mann-Whitney U test).  
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Figure 3.6. Gelsolin knock-down stimulates cell death of HCT 116 cells 
in anoikis model (flow cytometric analysis of propidium iodide staining). 
HCT 116 cells were treated with either gelsolin siRNA or control siRNA for 
72h, and collected for re-culture at density of 3x106 cells/24-well in non-
attachment plates in serum-free media for 48h. After that, cells were 
collected, fixed with ethanol, stained with propidium iodide and then 
subjected to cell cycle analysis by flow cytometry. (A) Representative results 
of cell cycle analysis of cells transfected with control siRNA, gelsolin siRNA 
(oligo 1) or gelsolin siRNA (oligo 3). Percentages of subG1 populations are 
indicated.  (B) Cell death in control cells, gelsolin siRNA knock-down cells 
(oligo 1 and oligo 3) was measured by percentages of subG1 population in 
cell cycle analysis. Data shown are mean± SD of three independent 
experiments.  *p-value <0.05 (Mann-Whitney U test) compare to control 
siRNA.  
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3.3.5.  Conditioned media of gelsolin-overexpressing cells protect HCT 116 
cells from apoptosis in anoikis model 
Literature suggests that gelsolin plays an important role in secretory 
pathway. Our results in this study showed that gelsolin promotes fibronectin 
secretion in HCT 116 cells and gelsolin protected HCT 116 cells from anoikis. 
We wanted to know if secreted molecules from gelsolin-overexpressing cells 
were the factors that protect HCT 1116 cells from apoptosis in the anoikis 
condition. In order to investigate this postulation, we used conditioned media 
from culture of gelsolin-overexpressing cells to culture HCT 116 cells in non-
attachment plates. To focus on the effects of fibronectin secretion from 
gelsolin-overexpressing cells, and rule out the effects of endogenous 
fibronectin in HCT 116 cells, HCT 116 cells were treated with fibronectin 
siRNA to knock down their endogenous fibronectin before being cultured in 
conditioned media from gelsolin-overexpressing cels.  
The effects on apoptosis were measured by annexin-V staining with 
flow cytometry. The basis for this assay is that when a cell undergoes 
apoptosis, phosphatidylserine, which is normally located on the inner side of 
plasma membrane, translocates to the outer side and is exposed for binding 
with annexin-V. FITC-conjugated annexin-V can be detected by flow 
cytometry and the intensity of annexin-V staining, therefore, represents 
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The set-up of this experiment is illustrated in the following diagram: 
 
Experimental set-up for investigation of the effects of conditioned media 
from gelsolin-overexpressing cells on HCT 116 cell apoptosis 
 
Briefly, gelsolin-overexpressing cells and vector control cells were 
cultured in serum-free media in attachment plates for 24h. Conditioned media 
of the cell culture were collected and put into non-attachment plates. In 
another setting, HCT 116 cells were transfected with fibronectin siRNA for 
48h and then re-cultured in the non-attachment plates with conditioned media 
from gelsolin-overexpressing cells or vector control cells described above. 
After 24h, fibronectin-knockdown HCT 116 cells were collected, stained with 
annexin-V and subjected to flow cytometry. As a negative control for 
apoptosis, wild-type HCT 116 cells were cultured in a standard culture 
condition, which is in attachment plates with complete media.  
Fibronectin-knockdown HCT 116 cells cultured in conditioned media 
from vector control cells experienced apoptosis in the anoikis model as shown 
by higher annexin-V staining compared to viable cells. When cultured in 
condition media from gelsolin-overexpressing cells (GSN O/E media from C1 
or C8), fibronectin-knockdown HCT 116 cells exhibited lower annexin-V 
staining than those cultured in media from vector control cells (Vector control 
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medium) (Figure 3.7), suggesting that condition media from gelsolin-
overexpressing cells contain anti-apoptotic factor(s). 
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Figure 3.7. Conditioned media from gelsolin-overexpressing cells protect 
cancer cells from anoikis-induced apoptosis. HCT 116 cells and gelsolin-
overexpressing cells were cultured in serum-free media in attachment plates in 
24h. Supernatants of the gelsolin-overexpressing cells and of the vector 
control cells were collected to put into non-attachment plates. Wild-type HCT 
116 cells were transfected with fibronectin siRNA for 48h, collected and re-
cultured in the non-attachment plates with conditioned media (collected from 
culture of gelsolin-overexpressing cells or vector control cells). After 24h, 
cells were collected for staining with annexin-V and flow cytometric analysis. 
(A) HCT 116 cells were transfected with either fibronectin siRNA or control 
siRNA for 48h. Western blot results showed that fibronectin was knocked 
down after transfection with fibronectin siRNA compared to control siRNA. 
(B) Histograms obtained from one representative experiment. The following 
are details of the experimental groups in the flow histograms: 
- Viable cells: as a negative control for apoptosis, HCT 116 cells were 
cultured in a standard culture condition (i.e. in attachment plates 
with complete media) for 24h, and stained with annexin-V before 
flow cytometry analysis. 
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- Unstained cells: as a negative control for annexin-V staining, HCT 
116 cells were cultured in a standard culture condition (i.e. in 
attachment plates with complete media) for 24h, and NOT stained 
with annexin-V. 
- Vector control medium: HCT 116 cells transfected with fibronectin 
siRNA and cultured in conditioned media from vector control cells. 
- GSN O/E medium (C1): HCT 116 cells transfected with fibronectin 
siRNA and cultured in conditioned media from gelsolin-
overexpressing cells C1. 
-  GSN O/E medium (C8): HCT 116 cells transfected with fibronectin 
siRNA and cultured in conditioned media from gelsolin-
overexpressing cells C8. 
(C) Quantitative analysis of median of annexin-V staining. Data shown are 
median ± SD of three independent experiments; *p-value<0.05 (Mann-
Whitney U test).   
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3.3.6.  Fibronectin rescues the effects of gelsolin knock-down on apoptosis 
of HCT 116 cells in anoikis model 
We have shown that gelsolin promotes survival of HCT 116 cells in the 
anoikis condition and gelsolin knock-down induces HCT 116 cell death. Our 
data also highlighted that gelsolin-overexpressing cells secret soluble factors 
that protect HCT 116 cells from apoptosis. As far as the important role of 
fibronectin in cell survival is concerned, it is possible that secreted fibronectin 
from gelsolin-overexpressing cells the factor that protected HCT 116 cells 
against apoptosis, and hence promoted HCT 116 cell survival. In this part of 
the study, we investigated the effects of gelsolin knock-down on apoptosis in 
the anoikis condition and examined whether exogenous fibronectin could 
reverse the effects of gelsolin knock-down on apoptosis.  
HCT 116 cells transfected with either gelsolin siRNA or control siRNA 
were re-cultured in non-attachment plates in serum-free media for 24h. After 
that, the cells were collected, washed and stained with annexin-V for 15min 
and subjected to flow cytometry. As a negative control for apoptosis, 
untransfected HCT 116 cells were cultured in a standard culture condition (i.e. 
in attachment plates with complete medium) for 24h, and then stained with 
annexin-V. In order to assess the effects of fibronectin on apoptosis, 
exogenous fibronectin 50g/ml was added to gelsolin-knockdown cells, which 
were cultured in the anoikis condition. Based on published investigations on 
the effects of fibronectin on cell survival, in which fibronectin was used to 
coat culture plate at concentration from 0.5-20g/ml [81, 82], the 
concentration of fibronectin was optimized and chosen at 50g/ml for this 
experiment. 
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As shown in figure 3.8, when gelsolin was knocked down using siRNA, 
more apoptosis was induced in the cells, indicated by higher annexin-V 
staining compared to cells treated with control siRNA. When cells were 
treated with exogenous fibronectin, gelsolin knock-down cells exhibited lower 
intensity of annexin-V staining, in a level comparable to control siRNA cells. 
These data indicate that fibronectin rescued the effects of gelsolin knock-down 
on apoptosis in HCT 116 cells. 
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Figure 3.8. Fibronectin rescued the effects of gelsolin knock-down on 
apoptosis in HCT 116 cells (flow cytometric analysis of annexin-V 
staining).  HCT 116 cells were transfected with either geloslin siRNA or 
control siRNA for 48h. The cells were then re-cultured in non-attachment 
plates in serum-free media for 24h. After that, the cells were collected and 
stained with annexin-V for 15min and subjected to flow cytometry (this group 
is labeled as ‘GSN siRNA’ and ‘Control siRNA’ in the representative flow 
histogram). As a negative control for apoptosis, untransfected HCT 116 cells 
were cultured in a standard culture condition (i.e. in attachment plates with 
complete media) for 24h, and then stained with annexin-V (this group is 
labeled as ‘Viable cells’). Exogenous fibronectin 50g/ml was added to 
gelsolin-knockdown cells, which were cultured in the anoikis condition (this 
group is labeled as ‘GSN siRNA + Fibronectin’ in the histogram). (A) 
Histograms from one representative experiment. (B) Quantitative analysis of 
median of annexin-V staining. Data shown are median ± SD of three 
independent experiments; *p-value<0.05 (Mann-Whitney U test).  
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3.3.7.  Fibronectin protects HCT 116 cells from apoptosis in anoikis model 
In the previous part, we have shown that fibronectin rescues the effects 
of gelsolin knock-down on apoptosis of HCT 116 cells in anoikis model. In 
this part of the study, we wanted to determine whether fibronectin expression 
and secretion in HCT 116 cells exerted the pro-survival effects.  
To investigate the effects of endogenous fibronectin on apoptosis, HCT 
116 cells were transfected with fibronectin siRNA or control siRNA before 
being re-cultured in non-attachment plates in serum-free media. To investigate 
the effects of exogenous fibronectin on cell survival, exogenous fibronectin 
was added with different concentrations 0-100g/ml to the culture media of 
fibronectin-deficient HCT116 cells (ie. fibronectin-knockdown cells) in non-
attachment plates. After 24h, cells were collected for staining with annexin-V 




Experimental set-up for investigating the effects of exogenous fibronectin 
on HCT 116 cell apoptosis. 
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Western blot analysis of transfected HCT 116 cells showed that 
fibronectin was knocked down after 48h transfection with fibronectin siRNA 
(Figure 3.9A). The flow cytometric results displayed that when fibronectin 
was knocked down, there was increased annexin-V staining intensity 
compared to transfection with control siRNA (Figure 3.9B), indicating that 
endogenous fibronectin protected HCT 116 cells from apoptosis in the anoikis 
condition. In the presence of exogenous fibronectin, fibronectin-knockdown 
HCT 116 cells remained detached from the non-attachment plates and were 
collected without trypsinization. Figure 3.9C shows that exogenous fibronectin 
treatment resulted in lower annexin-V staining intensity in a dose-dependent 
manner. Taken together, these data indicated that both endogenous and 
exogenous fibronectin protected HCT 116 cells from apoptosis in the anoikis 
condition. 
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Figure 3.9. Fibronectin expression and secretion protects HCT 116 cells 
from apoptosis in anoikis model. 
HCT 116 cells were transfected with either fibronectin siRNA or control 
siRNA for 48h. After transfection, cells were re-cultured in non-attachment 
plates in serum-free media for 24h, and then collected, washed and stained 
with annexin-V for 15min before being subjected to flow cytometry.  
(A) Histograms obtained from one representative experiment. As a negative 
control for apoptosis, untransfected HCT 116 cells were cultured in 
attachment plates in complete medium and stained with annexin-V (labeled as 
‘Viable cells’ in the flow histogram). Cells transfected with fibronectin siRNA 
and control siRNA are respectively labelled as ‘Fibronectin siRNA’ and 
‘Control siRNA’ in the flow histogram (upper). Fibronectin-knockdown cells 
in the anoikis condition were treated with exogenous fibronectin at the 
concentration of 0, 50 or 100g/ml for 24h before flow cytometric analysis 
(lower).  
(B) Quantitative analysis of median of annexin-V staining. (FNsiRNA: 
Fibronectin siRNA; FNsiRNA+FN50: Fibronectin siRNA+Fibronectin 
50g/ml; FNsiRNA+FN100: Fibronectin siRNA+Fibronectin 100g/ml). Data 
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shown are median ± SD of three independent experiments; *p-value<0.05 
(Mann-Whitney U test). Higher annexin-V staining intensity was detected in 
cells with fibronectin knock-down. In addition, exogenous fibronectin reduced 
annexin-V staining intensity in fibronectin-knockdown HCT 116 cells in a 
dose-dependent manner.  
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3.3.8.  Fibronectin stimulates activation of Akt signaling pathway in HCT 
116 cells 
To further assess the significance of exogenous fibronectin in HCT 116 
cell survival, we investigated if exogenous fibronectin could stimulate 
activation of survival signaling in our anoikis model. HCT 116 cells were 
cultured in serum-free media in non-attachment plates and stimulated with 
exogenous fibronectin at different concentrations. The cells were collected at 
different time-points for Western blot analysis. Figure 3.10 shows that Akt 
signaling was activated in HCT 116 cells upon treatment with fibronectin as 
shown by increased levels of phospho-Akt. The effects of exogenous 
fibronectin on activating Akt signaling were dependent on treatment duration 
as well as fibronectin concentration. 
  







Figure 3.10. Fibronectin promotes Akt signaling in HCT 116 cells.  HCT 
116 cells were cultured in non-attachment plates in serum-free media. (A) 
Fibronectin was added into the HCT 116 cell culture at a concentration of 
100g/ml. Cells were collected at different time points 0, 15, 30 and 60min 
and 25g of extracted proteins were analyzed by Western blot to measure 
phospho-Akt (p-Akt) and total Akt expression. (A) A representative western 
blot and (B) quantitative analysis of western blots; data shown are mean ± 
SD of three independent experiments; *p-value<0.05 (Mann-Whitney U test). 
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3.4. DISCUSSION 
3.4.1. Gelsolin regulates fibronectin expression and secretion in colorectal 
cancer cells 
Secretion of fibronectin, an important survival stimulator, has been 
shown in some cancers such as melanoma or hepatocellular carcinoma [71, 
72]. Our data showed that colorectal cancer cells, including HCT116, its 
metastatic derivative E1, DLD-1 and RKO, also expressed and secreted 
fibronectin.  
Colorectal cancer is heterogeneous with various mutations. The most 
common mutations in colorectal cancers include KRAS, BRAF and APC [113, 
114]. The three cell lines in this study, HCT 116, RKO and DLD-1 
respectively have mutations in KRAS, BRAF and APC genes [115]. Therefore, 
the chosen cell lines can represent, to some extent, the most common genetic 
changes in colorectal cancers. However, there is no connection between the 
documented mutations in the cell lines and fibronectin expression and 
secretion. Among the above-mentioned mutated genes, BRAF is potentially 
related to fibronectin expression. BRAF is a proto-oncogene downstream of 
RAS and upstream of MAPK. Mutations in BRAF are reported to result in 
enhanced malignant proliferation. On the other hand, MAPK has been 
reported to regulate HGF-induced fibronectin expression in melanoma [71]. 
Therefore, it is possible that cells with activated BRAF may induce fibronectin 
upregulation. However, RKO cells with hyper-activating BRAF [116] have 
low fibronectin expression, and HCT 116 cells with wild-type BRAF express 
high level of fibronectin. Therefore, documented mutations cannot help to 
explain the difference in fibronectin expression in HCT 116, RKO and DLD-1. 
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Our data also show that the expression and secretion of fibronectin 
detected in colorectal cancer cell lines HCT 116, E1, RKO and DLD-1 
correlate with intracellular gelsolin level. This finding suggests the 
involvement of gelsolin in regulating fibronectin expression and/or secretion. 
In addition, literature has suggested the participation of gelsolin in ECM 
remodeling, in regulating gene regulation and vesicle-mediated secretion. The 
information prompted us to investigate if gelsolin regulated fibronectin 
expression and secretion. In order to do that, we modulated gelsolin levels by 
the gain-of-function and loss-of-function models. Our results demonstrated 
that when gelsolin was overexpressed in HCT 116 cells, there was 
upregulation of fibronectin (at both protein and mRNA levels) and increased 
fibronectin secretion. Consistently, when gelsolin was knocked down, 
fibronectin expression (protein and mRNA) and secretion were suppressed 
accordingly. These data indicate that gelsolin upregulates fibronectin 
expression as well as secretion of fibronectin.  
Our results not only reveal gelsolin as a novel regulator of fibronectin, 
an important part of the ECM, but also suggest that gelsolin regulates the 
fibronectin gene and possibly the secretory pathways that involved in 
fibronectin secretion. These findings are in accordance with the previous 
studies that suggested the role of gelsolin in vesicle-mediated secretion. 
Gelsolin regulates actin remodeling, which is important in the regulation of 
secretion pathways [22]. Gelsolin has also been shown to be involved in 
regulated secretion of insulin by a mechanism independent of actin regulation. 
Kalwat M.A. et al. [23] demonstrated that gelsolin interacted with the SNARE 
protein Syn4, which was important for the fusion of insulin vesicles to plasma 
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membrane for exocytosis. When cells were stimulated with glucose, gelsolin 
was released from the binding with Syn4, allowing insulin vesicles to fuse 
with Syn4 and then were secreted outside. On the other hand, literature has 
shown the roles of gelsolin as a transcription co-activator of several 
transcription factors or co-activators. Gelsolin promoted nuclear translocation 
of androgen receptor and thyroid hormone receptor-1 resulting in increased 
androgen receptor activity and thyroid hormone receptor-1 activity 
respectively [18, 19]. In addition, gelsolin was shown to regulate the 
transcription factors YAP/TAZ and p53. Gelsolin localized YAP/TAZ and p53 
in cytoplasm, leading to suppression of YAP/TAZ and p53 signaling. When 
gelsolin was knocked down, YAP/TAZ and p53 translocated to the nucleus 
and exerted their effects on transcription of various downstream genes [20, 21]. 
Our findings about the possible roles of gelsolin in the regulation of the 
fibronectin gene and fibronectin secretion process contribute to elucidate the 
diverse and potent roles of gelsolin in cell biology, besides its famous role as a 
regulator of actin dynamics.   
 
3.4.2. Gelsolin protects cancer cells from apoptosis and cell death in 
anoikis condition 
Gelsolin has been shown to exert anti-apoptotic effects in several studies 
in vitro [14, 15]. In addition, higher gelsolin expression was associated with 
poorer prognosis in clinical research [30, 31]. Our findings in this study are in 
agreement with the anti-apoptotic and pro-survival effects of gelsolin 
described above. Our results showed that when cultured in the anoikis 
condition, gelsolin-overexpressing cells exhibited less cell death compared to 
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control cells. Consistently, when gelsolin was knocked down with siRNA, 
there was more cell death in comparison to control groups.  
The anoikis model used in this research was adapted from previous 
studies relating to anoikis and cancer development [111, 117]. In our study, 
HCT116 cells were cultured in serum-free media to avoid the effects of 
exogenous fibronectin present in serum. In addition, to rule out the effects of 
massive signals triggered by binding of cancer cells to attachment plates [118], 
we cultured cells in non-attachment plates, which had been coated with 
hydrogel to prevent adhesion-induced signaling.  
Anoikis is a programmed cell death due to loss of anchorage to the ECM. 
While normal cells undergo anoikis in non-attachment conditions, cancer cells 
can acquire anchorage-independence or anoikis-resistance [119] to survive in 
stress conditions or during dissemination process. The findings from our study 
suggest a potential mechanism by which cancer cells can survive anoikis 
condition. Taking the anti-apoptosis and pro-survival effects of gelsolin into 
account, it is possible that cancer cells that express high levels of gelsolin are 
able to promote their own survival, and hence do not need to rely on 
anchorage-related survival signaling during invasion and metastasis. This 
postulation also helps to partially explain the increased gelsolin expression in 
cells with high invasive or metastatic capacity as well as high gelsolin 
expression in cancer invasion and metastasis. 
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3.4.3. Gelsolin promotes HCT 116 survival by upregulating fibronectin 
expression and secretion 
Our results showed that gelsolin upregulated fibronectin expression and 
secretion in colorectal cancer cells. In addition, gelsolin promoted HCT 116 
cell survival. Taking the reported pro-survival effects of fibronectin into 
account, we postulated that gelsolin-regulated fibronectin expression and 
secretion possibly played a part in the pro-survival effects of gelsolin on HCT 
116 cells in the anoikis condition. Indeed, both endogenous and exogenous 
fibronectin protected HCT 116 cells from apoptosis in the anoikis condition. 
In addition, conditioned media from gelsolin-overexpressing cells, which had 
been shown to contain high levels of secreted fibronectin, also exerted pro-
survival effects on HCT 116 cells. The results suggest that secreted fibronectin 
by gelsolin-overexpressing cells was possibly the factor that protected HCT 
116 cells from apoptosis. This postulation was supported by our findings 
showing that exogenous fibronectin inhibited apoptosis and also stimulated the 
pro-survival Akt signaling pathway. Moreover, exogenous fibronectin could 
rescue the apoptotic effects induced by gelsolin knock-down.  
These findings are in accordance with numerous studies emphasizing the 
roles of fibronectin in the survival of both normal and tumor cells [76, 81, 84].  
The stimulation of Akt signaling by fibronectin is also supported by previous 
studies [81, 82]. Akt signaling is widely known for its protective effects 
against apoptosis induced by serum deprivation, inflammatory cytokines or 
UV-irradiation in different cell types [120-122]. Akt confers anti-apoptotic  
effects by inhibiting pro-apoptotic factors such as p53 or the Bcl-2-associated 
death promoter (BAD) or stimulating anti-apoptotic molecules such as NFB 
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or Bcl-xL [123].  In agreement with our findings, it has been shown in 
literature that pre-coated fibronectin in attachment plates activated Akt 
signaling [81, 82]. However, of note is that in fibronectin-coated plates, cell 
survival is possibly stimulated by not only fibronectin but also mechanical 
forces dependent on matrix physical properties such as stiffness and 
topography [20, 124]. Our anchorange-independent model used in this study 
rules out the effect of the mechanical factors, and hence confirms that secreted 
fibronectin promotes cancer cell survival by activation of Akt. In addition, the 
finding that increased Akt phosphorylation in HCT 116 cells not treated with 
exogenous fibronectin at 30min and 60min suggests Akt could be activated by 
other factors rather than the exogenous fibronectin. Of note is that HCT 116 
cells have significant endogenous level of fibronectin and can secrete 
fibronectin. Therefore, it is possible that fibronectin was secreted by HCT 116 
cells and activated Akt signaling in the cells in a paracrine mechanism. 
Based on the findings on pro-survival effects of both endogenous and 
exogenous fibronectin, our findings suggest that gelsolin protects cancer cell 
from apoptosis by upregulating fibronectin expression and secretion. Gelsolin 
has been reported to be involved in promoting cancer survival. Higher 
expression of gelsolin correlated with poorer prognosis in patients at later 
stages or recurrent lung cancer [30, 31]. As shown in our previous study, high 
gelsolin expression was detected at the invasive front of metastatic tumor in 
liver [34]. Moreover, cell-based studies have indicated that the association of 
gelsolin with cancer survival was not only a correlative but also causative 
relation. Full-length gelsolin and C-terminal half of gelsolin were 
demonstrated to exhibit pro-survival effects by inhibiting apoptosis [14, 15]. 
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The anti-apoptotic effects of gelsolin was demonstrated due to its ability to 
bind and close voltage-dependent anion channel (VDAC), which inhibited 
cytochrome c release from mitochondria resulting in attenuated caspases 3, 8, 
9 [14, 15]. In this study, we propose a novel mechanism by which gelsolin 
protects cancer cells from apoptosis and cell death. By upregulating the 
expression and secretion of fibronectin, gelsolin indirectly exhibits anti-
apoptotic capacity and promotes cancer cell survival. 
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SUMMARY 
In this chapter, we demonstrated that gelsolin upregulated fibronectin 
expression and secretion in colorectal cancer HCT 116 cells. In addition, 
gelsolin exhibited pro-survival and anti-apoptotic effects in HCT 116 cells in 
an anoikis condition. Conditioned media obtained from gelsolin over-
expressing cells protected HCT 116 cells against apoptosis, gelsolin-
overexpressing cells secreted unknown factors that promoted HCT 116 cells 
survival. Our results suggested that one of the secreted factors that promoted 
HCT 116 cell survival was fibronectin. Fibronectin protected HCT 116 cells 
from apoptosis and stimulated Akt signaling. Moreover, fibronectin rescued 
the apoptotic effect of gelsolin knock-down on HCT 116 cells. Taken together, 
these findings elucidated an important role of gelsolin in cancer cell survival 
in the anoikis condition by promoting fibronectin expression and secretion. 
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4.1. BACKGROUND 
Regulation of fibronectin expression and secretion is not yet fully 
understood. Studies in different cells show diverse signaling pathways 
involved in fibronectin expression. Normal cells such as coronary artery 
smooth muscle cells or osteoblasts express fibronectin upon stimulation of 
growth factors such as TNF-and bFGF [62-64]. TNF-induces nitric oxide-
dependent post-transcriptional modification of the fibronectin gene, whereas 
bFGF activates NFB via PLC2/PKCc-Src signaling. However, in 
glioblastoma or melanoma cells, the fibronectin gene has been shown to be 
regulated by the transcription factor EGR-1 upon stimulation of hepatocyte 
growth factor (HGF) [67, 68]. The limited information about fibronectin 
regulation necessitates further research on the factors that control fibronectin 
expression. 
Besides its famous role as an actin regulator, gelsolin has been shown to 
modulate various genes by either promoting or suppressing their transcription 
factors or transcription co-activators. When in cytoplasm, fibronectin binds to 
transcription co-activators YAP/TAZ or p53, inhibiting their translocation to 
the nucleus. The downstream genes of YAP/TAZ and p53 are therefore down-
regulated by gelsolin overexpression [20, 21]. On the other hand, gelsolin in 
the nucleus binds to androgen receptor at its DNA-binding and ligand binding 
sites to promote androgen receptor activity in human prostate cancer cells [18]. 
Collectively, these findings have highlighted the involvement of gelsolin in 
gene transcription. 
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In the previous chapter, we have demonstrated that gelsolin promoted 
the secretion of fibronecin by colorectal cancer cells HCT 116. In addition, 
gelsolin upregulated fibronectin expression in both protein and mRNA levels. 
In this part of the study, we investigated whether gelsolin exerted the 
regulation effects on fibronectin expression and secretion by affecting the 




1) To investigate the involvement of the transcription factor EGR-1 in 
gelsolin-regulated expression of fibronectin 
2) To investigate the involvement of the transcription factor NFB in gelsolin-
regulated expression of fibronectin  
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4.3. RESULTS 
4.3.1. Fibronectin expression in HCT 116 cells is stimulated by hepatocyte 
growth factor 
Hepatocyte growth factor (HGF) was shown to stimulate fibronectin 
expression in melanoma cells [71]. We investigated if HGF upregulated 
fibronectin in colorectal cancer HCT 116 cells. Cells were cultured in serum-
free media with HGF at different concentrations. After 24h, cells were 
collected for Western blot and real-time PCR. 
As shown in Figure 4.1, while gelsolin expression was not affected by 
HGF, fibronectin mRNA was upregulated by HGF stimulation at 
concentrations from 10ng/ml. Consistently, stimulation of HCT 116 cells with 
HGF induced increased fibronectin expression at protein level, whilst HGF did 
not affect gelsolin expression. 
 
  












Figure 4.1. HGF stimulates fibronectin expression in HCT 116 cells. HCT 
116 cells were cultured in serum-free media. HGFwith concentrations of 0, 10, 
50, 100 ng/ml was added into culture media of HCT 116 cells.  
(A&B) After 24h, cells were collected for real-time PCR to measure (A) 
fibronectin and (B) gelsolin mRNA levels. Data shown are mean± SD of three 
independent experiments.  *p-value <0.05 (Mann-Whitney U test).  
(C) After 24h of stimulation with HGF, 25g of extracted proteins were 
analyzed by Western blot. A representative Western blot (upper) and 
quantitative analysis of Western blots (lower); data shown are mean ± SD of 
three independent experiments; *p-value<0.05 (Mann-Whitney U test) 
compared to no treatment (0ng/ml) in the same group.  
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4.3.2. Hepatocyte growth factor stimulates EGR-1 in HCT 116 cells 
HGF was reported to activate EGR-1 expression, which is a known 
regulator of the fibronectin gene in melanoma cells and hepatocellular 
carcinoma cells [71, 125]. We examined whether HGF enhanced EGR-1 
expression in HCT 116 cells. HCT 116 cells were cultured in serum-free 
media and stimulated with HGF 10ng/ml for different periods of time. After 
that the cells were collected for real-time PCR or Western blot. 
 As demonstrated in Figure 4.2A, EGR-1 mRNA was observed to be 
upregulated at 60-120 minutes after HGF treatment, with highest levels 
observed at 60 minutes. In agreement with that, upon stimulation with HGF, 
EGR-1 protein expression in HCT 116 cells was also enhanced at 60 and 120 
minutes after HGF treatment (Figure 4.2B). 
  








Figure 4.2. HGF stimulates EGR-1 expression in HCT 116 cells. HCT 116 
cells were cultured in serum-free media. 10 ng/ml HGF was added into culture 
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media of HCT 116 cells. After 0, 30, 60 and 120 minutes, cells were collected 
for real-time PCR (A) or Western blot (25g of extracted proteins were 
loaded) (B); data shown in (A) are mean± SD of three independent 
experiments.  *p-value <0.05, **p-value <0.01 (Mann-Whitney U test). (B) A 
representative Western blot (upper) and quantitative analysis of Western blots 
(lower); data shown are mean ± SD of three independent experiments; *p-
value<0.05 (Mann-Whitney U test) compared to 0 min in the same group.  
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4.3.3. Gelsolin does not affect EGR-1 expression and activity in HCT 116 
cells 
 We have demonstrated that HGF upregulated fibronectin as well as the 
known regulator of the fibronectin gene, EGR-1 [71]. In addition, in the 
previous chapter, our data indicated that gelsolin upregulated fibronectin 
expression. In order to determine whether gelsolin upregulated fibronectin 
gene via HGF-EGR-1 signaling, we investigated the roles of gelsolin on EGR-
1 expression and activity. 
 We modulated gelsolin levels by overexpression or siRNA knock-down 
and measured EGR-1 expression by Western blot. EGR-1 activity was 
measured by dual-luciferase reporter assay. HCT 116, vector control cells and 
gelsolin-overexpressing cells were transfected with EGR-1-responsive 
luciferase reporter, negative control, or positive control luciferase constructs. 
To test the effects of gelsolin knock-down on EGR-1 activity, HCT 116 cells 
were co-transfected with individual luciferase constructs as well as either 
gelsolin siRNA or control siRNA. Following transfection, cells were harvested 
for cell lysis and measurement of luciferase activity.  
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As shown in Figure 4.3, gelsolin overexpression (in C1 and C8 cells) did 
not alter either EGR-1 expression nor EGR-1 transcriptional activity compared 
to HCT 116 and vector control cells. Consistently, Figure 4.4 shows that 
neither EGR-1 expression nor transcriptional activity was affected by gelsolin 
knock-down. These data indicate that gelsolin does not regulate EGR-1 
expression nor activity, and thus fibronectin regulation by gelsolin is unlikely 
via gelsolin’s influence on EGR-1. 
  




Figure 4.3. Gelsolin overexpression does not affect EGR-1 expression and 
transcriptional activity. (A) Western blot of EGR-1 expression in HCT 116, 
vector control cells and gelsolin-overexpressing cells (C1 and C8) (25g of 
extracted proteins were analyzed). (B) EGR-1-responsive reporter, negative 
control, and positive control constructs were mixed with the transfection 
reagent Lipofectamine 2000 and delivered to HCT 116, vector control and 
gelsolin-overexpressing cells (C1, C8). After 24h, culture media was replaced 
with serum-free media and incubated for another 24h. Following transfection, 
cells were harvested with cell lysis buffer and luciferase activity was measured 
using the Dual-Luciferase Assay System (Promega). Transcriptional activity 
was calculated from the ratio between firefly/renilla from experimental 
samples and firefly/renilla from negative control transfection (refer to main 
text for the formula). Data shown are mean± SD of three independent 
experiments.  





Figure 4.4. Gelsolin knock-down does not affect EGR-1 expression and 
transcriptional activity. (A) Western blot of EGR-1 expression in HCT 116 
cells transfected with either of control siRNA or gelsolin siRNA (25g of 
extracted proteins were analyzed). (B) EGR-1-responsive reporter, negative 
control, and positive control constructs were mixed with gelsolin siRNA or 
control siRNA. The nucleic acids were then mixed with Lipofectamine 2000 
and transfected to HCT 116 cells. After 24h, culture media was replaced with 
serum-free media and incubated for another 24h. Following co-transfection, 
cells were lysed and luciferase activity was measured using the Dual-
Luciferase Assay System (Promega). Transcriptional activity was calculated 
from the ratio between firefly/renilla from experimental samples and 
firefly/renilla from negative control transfection (refer to main text for the 
formula). Data shown are mean± SD of three independent experiments.  
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4.3.4. Fibronectin expression in HCT 116 cells is regulated by NFB 
NFB has been shown to upregulate fibronectin expression in normal 
cells such as osteoblasts or hepatocytes. In order to investigate the 
involvement of NFB in fibronectin expression in HCT 116 cells, cells were 
treated with NFB inhibitor, BAY 11-7085 at different concentration 0, 10 or 
20 ng/ml, for 12 h, and then collected for Western blot. At these 
concentrations, BAY 11-7085 was shown not to induce apoptosis nor cell 
death in HCT 116 cells [126]. As shown in Figure 4.5, NFB inhibitor 
reduced fibronectin expression in HCT 116 cells. This result suggests that the 
fibronectin level in HCT 116 cells is regulated by NFB. 
We next investigated if NFB activation promoted fibronectin 
expression in HCT 116 cells. HCT 116 cells cultured in serum-free media 
were stimulated with different concentrations of TNF0, 10, 20 or 40ng/ml.  
NFB was shown to be activated by TNF at these concentrations [127]. 
After 12h, cells were collected for real-time PCR or Western blot. Figure 4.6 
shows that TNF increased fibronectin mRNA to about 2-3 times higher than 
in the absence of TNF, whereas TNFdid not affect gelsolin mRNA levels 
in HCT 116 cells. These findings were substantiated with Western blot results, 
which showed that TNF stimulates the expression of fibronectin but not that 
of gelsolin.  
  






Figure 4.5. NFB inhibitor BAY 11-7085 attenuates fibronectin 
expression in HCT116 cells. HCT 116 cells were cultured in serum-free 
media. BAY 11-7085 at the concentrations of 0, 10, 20 ng/ml was added into 
cultured cells. After 12h, cells were collected for Western blot analysis (25g 
of extracted proteins were analyzed). A representative Western blot (upper) 
and quantitative analysis of Western blots (lower); data shown are mean ± SD 
of three independent experiments; *p-value<0.05 (Mann-Whitney U test) 
compared to no treatment (0ng/ml) in the same group.  
 
  










Figure 4.6. TNFstimulates fibronectin expression in HCT 116 cells. HCT 
116 cells were cultured in serum-free media. TNFwith concentrations of 0, 
10, 20, 40 ng/ml was added into culture media of HCT 116 cells. After 12h, 
cells were collected for real-time PCR to measure fibronectin mRNA (A) and 
gelsolin mRNA (B) and Western blot (25g of extracted proteins were 
analyzed) (C). Data shown in (A) and (B) are mean± SD of three independent 
experiments.  *p-value <0.05 (Mann-Whitney U test). (C) A representative 
Western blot (upper) and quantitative analysis of Western blots (lower); data 
shown are mean ± SD of three independent experiments; *p-value<0.05 
(Mann-Whitney U test) compared to no treatment (0ng/ml) in the same group.  
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4.3.5. Gelsolin stimulates NFB activity in HCT 116 cells 
We have demonstrated that TNF a known stimulator of NFB, 
upregulated fibronectin expression in HCT 116 cells but did not affect gelsolin 
levels. We also showed in the previous chapter that gelsolin upregulated 
fibronectin expression. In order to ascertain whether gelsolin upregulated the 
fibronectin gene via NFB signaling, we investigated the roles of gelsolin on 
NFB expression and activity. 
 We modulated gelsolin levels by overexpression or siRNA knock-down 
and measured NFB expression by Western blot. NFB activity was measured 
by dual-luciferase reporter assay.  HCT 116, vector control cells and gelsolin-
overexpressing cells were transfected with NFB-responsive luciferase 
reporter, negative control, or positive control luciferase constructs. To test the 
effects of gelsolin knock-down on NFB activity, HCT 116 cells were co-
transfected with individual luciferase constructs as well as with either gelsolin 
siRNA or control siRNA. Following transfection, cells were harvested for cell 
lysis and measurement of luciferase activity.  
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Our data showed that although NFB expression was not affected by 
gelsolin overexpression, NFB activity was significantly enhanced in gelsolin-
overexpressing cells (C1 and C8 cells) compared to wild-type HCT 116 cells 
and vector control cells (Figure 4.7). Consistent with this, gelsolin knock-
down in HCT 116 cells did not alter NFB expression but attenuated NFB 
activity compared to control siRNA-transfected cells. These findings were 
further confirmed by knock-down of gelsolin in gelsolin-overexpressing cells 
and other colorectal cancer cells DLD-1 and RKO (Figure 4.8). Collectively, 
our data suggest that gelsolin stimulates NFB activity but not NFB 
expression in colorectal cancer cells. 
  




Figure 4.7. Gelsolin overexpression promotes NFB activity but not NFB 
expression. (A) Western blot of NFB expression in HCT 116, vector control 
cells and gelsolin-overexpressing cells (C1 and C8) (25g of extracted 
proteins were analyzed). (B) Transcriptional activity of NFB in gelsolin-
overexpressing cells and control cells. NFB-responsive reporter, negative 
control, and positive control constructs were transfected to HCT 116, vector 
control cells and gelsolin-overexpressing cells (C1, C8). After 24h, culture 
media was replaced with serum-free media and incubated for another 24h. 
Following transfection, cells were harvested with cell lysis buffer and 
luciferase activity was measured using the Dual-Luciferase Assay System 
(Promega). Transcriptional activity of NFB was calculated from the ratio 
between firefly/renilla from experimental samples and firefly/renilla from 
negative control transfections (refer to main text for the formula). Data shown 
are mean± SD of three independent experiments.  *p-value <0.05 (Mann-
Whitney U test). 






Figure 4.8. Gelsolin knock-down attenuates NFB activity but not NFB 
expression. (A) Western blot of NFB expression in HCT 116 cells 
transfected with either of control siRNA or gelsolin siRNA (oligo 1 or oligo 3) 
(25g of extracted proteins were analyzed). (B) Transcriptional activity of 
NFB in gelsolin-knockdown cells and control cells. NFB-responsive 
luciferase reporter, negative control, or positive control constructs was mixed 
with gelsolin siRNA or control siRNA. The combination of constructs were 
then transfected into HCT 116 cells, RKO or DLD-1. After 24h, culture media 
was replaced with serum-free media and incubated for another 24h. Following 
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co-transfection, cells were lysed and luciferase activity was measured using 
the Dual-Luciferase Assay System (Promega). Transcriptional activity of 
NFB was calculated from the ratio between firefly/renilla from experimental 
samples and firefly/renilla from negative control transfections (refer to 
maintext for the formula). NFB transcriptional activity was normalised 
within each cell line against its relevant control siRNA-treated sample. Data 
shown in are mean± SD of three independent experiments.  *p-value <0.05 
(Mann-Whitney U test). 
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4.3.6. Gelsolin promotes fibronectin expression by activating NFB 
activity 
In the previous parts of this chapter, we have shown that NFB 
upregulated fibronectin expression and gelsolin activated NFB activity. We 
explored whether gelsolin upregulated fibronectin expression by activating 
NFB activity. 
Gelsolin-overexpressing cells and vector control cells were cultured in 
serum-free media with or without NFB inhibitor, BAY 11-7085. After 12 h, 
cells were collected for Western blot. Figure 4.9 shows that gelsolin-
overexpressing cells exhibited higher fibronectin expression compared to 
vector control cells. However, when cells were treated with NFB inhibitor, 
fibronectin expression in gelsolin-overexpressing cells was reduced to similar 
levels as untreated vector control cells. This shows that the upregulation of 
fibronectin by gelsolin could be attenuated by NFB inhibition. Taken 
together with our previous findings that gelsolin stimulates NFB activity, 
these results suggest gelsolin upregulates fibronectin expression through the 
NFB pathway. 
  







Figure 4.9. Gelsolin-upregulated fibronectin expression is attenuated by 
NFB inhibition. Gelsolin-overexpressing cells and vector control cells were 
cultured in serum-free media. BAY 11-7085, NFB inhibitor, at the 
concentration of 20ng/ml was added into cultured cells. After 12 h, the cells 
were collected for Western blot analysis (40g of extracted proteins were 
analyzed). A representative Western blot (upper) and quantitative analysis of 
Western blots (lower); data shown are mean ± SD of three independent 
experiments; *p-value<0.05 (Mann-Whitney U test).  
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4.4. DISCUSSION 
4.4.1. Fibronectin expression is regulated by the transcription factors 
EGR-1 and NFB in HCT 116 cells 
In this chapter, we have shown that fibronectin expression in HCT 116 
cells was upregulated by HGF. Furthermore, HGF stimulated EGR-1 
expression. Fibronectin upregulation was also induced by TNF-treatment, a 
known stimulator of NFB pathway.  
The two transcription factors EGR-1 and NFB were mentioned in 
several studies to be involved in regulating the fibronectin gene. It was 
reported that, in normal cells such as hepatocytes and osteoblasts, fibronectin 
expression is upregulated by NFB upon different stimulations. TNF-, a 
known regulator of NFB, stimulated fibronectin expression in coronary 
artery smooth muscle cells by a posttranscriptional mechanism dependent on  
nitric oxide [62, 63]. In osteoblasts, NFB was activated by basic fibroblast 
growth factor (bFGF) via PLC2/PKCc-Src signaling, resulting in enhanced 
fibronectin synthesis [64]. In rat hepatocytes, the transcription of fibronectin 
was also regulated by NFB by the binding of p65/p65 homodimer to the 
fibronectin promoter [65].  
The fibronectin gene has also been shown to be regulated in cancer cells 
by EGR-1, which plays important roles in regulating cell proliferation and 
differentiation. Overexpression of EGR-1 in human glioblastoma cells was 
observed to result in high fibronectin expression [67]. EGR-1 exerted its effect 
by binding to 2 binding sites between -75 to -52 and -4 to +14 of the 
fibronectin promoter. In melanoma cell lines, EGR-1 also bound to fibronectin 
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promoter upon stimulation by HGF via activation of mitogen-activated protein 
kinase MAPK. Overexpression of NGFI-A binding protein NAB2, the co-
suppressor of EGR-1 in melanoma cells, reversed the effect of HGF on 
fibronectin expression [68]. 
Our findings are in accordance with previous studies showing that both 
TNF and HGF induce upregulation of the fibronectin gene. In HCT 116 cells, 
TNF upregulated fibronectin expression at both mRNA and protein levels in 
a dose-dependent manner. As TNF did not affect gelsolin expression, TNF 
may regulate fibronectin a gelsolin-independent mechanism. However, it is 
also possible that gelsolin was involved as a downstream effector of the TNF 
signaling. Further studies should be conducted to clarify these possibilities. 
The effects of HGF on fibronectin expression are different from what we 
observed with TNF. Our data shows that the effects of HGF on fibronectin 
mRNA saturated at HGF 10ng/ml, and there were no significant differences 
when concentration of HGF was increased to 50 or 100ng/ml. However, 
Western blot results showed that there was a slight decrease of fibronectin 
expression at protein level. This phenomenon can be explained by possible 
effects of HGF on secretory pathways. HGF was previously shown to promote 
secretion of prostaglandin E2 by lung cancer cell line H23 [128] and 
exocytosis of lysosomal enzymes by neutrophils [129]. Therefore, it is 
possible that, in our study, increased level of HGF promoted fibronectin 
secretion in HCT 116 cells, and enhanced fibronectin secretion resulted in 
slightly lower intracellular fibronectin. In order to clarify the postulation, 
fibronectin secretion should be measured and effects of HGF at 50ng/ml and 
100ng/ml on secretory pathways should be studied. 
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While different studies showed the effects either of EGR-1 or NFB, our 
results suggest that both transcription factors EGR-1 and NFB were involved 
in the regulation of the fibronectin gene in HCT 116 cells. As a crosstalk 
between EGR-1 and NFB has been reported [130], our findings do not 
exclude a possibility that the 2 transcription factors may work in tandem to 
induce transcription of fibronectin.     
 
4.4.2. Gelsolin enhances NFB activity but not EGR-1 to upregulate 
fibronectin expression 
We have shown that fibronectin expression in HCT 116 cells was 
stimulated by both EGR-1 and NFB transcription factors. In addition, our 
data suggested that gelsolin upregulated fibronectin expression by promoting 
NFB activity but not EGR-1.  
Our findings showing fibronectin gene regulation by gelsolin are in 
agreement with reported functions of gelsolin in modulating transcription co-
activators or transcription factors. Gelsolin was shown to regulate gene 
transcription via two main mechanisms:  
(1) Cytoplasmic gelsolin directly binds to transcription co-activators/factors, 
inhibiting their translocation to the nucleus. For example, it was demonstrated 
that binding of gelsolin to YAP/TAZ transcription factors restricted their 
localization to the cytoplasm, leading to down-regulation of transcriptional 
activity. Similar effects of gelsolin on p53 and its transcriptional activity were 
also reported. [20, 21]. 
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(2) Nuclear gelsolin interacts with transcription co-activators/factors to 
promote their activity. Gelsolin was shown to interact with androgen receptor 
at its DNA-binding and ligand-binding sites to promote androgen receptor 
activity in human prostate cancer cells [18]. In a thyroid cancer mouse model, 
the C-terminus of gelsolin was shown to interact with the DNA binding 
sequence of thyroid hormone receptor-1, resulting in reduced effects of 
thyroid hormone receptor on tumor progression [19]. 
Our results in this chapter indicated that gelsolin overexpression or 
knock-down did not affect either EGR-1 nor NFB expression. However 
NFB activity was significantly stimulated by gelsolin overexpression and 
inhibited by gelsolin knock-down. Nevertheless, how gelsolin activates NFB 
activity remains to be elucidated in future studies. 
In general, changes of NFB activity can be explained by the following 
possibilities [131-133]:  
(1) Enhanced NFB expression, which leads to increased nuclear 
transclocation of NFB, and hence enhanced NFB activity; 
(2) Reduced level of NFB inhibitors: In normal conditions NFB exists in 
binding with the inhibitory kappa B proteins, IB, which mask the nuclear 
signal of NFB. When cells are stimulated, IB proteins are phosphorylated 
and degraded by ubiquitination, allowing NFB to translocate into the nucleus 
for transcription of various NFB target genes. Therefore, reduction of IB 
proteins usually results in increased nuclear translocation of NFB as well as 
enhanced NFB activity;    
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(3) Increased NFB nuclear translocation, which results in an increase of 
NFB activity; 
 (4) Increased NFB activity by direct stimulation: NFB activity was 
reported to be directly modulated by post-translational modification. Various 
studies have shown that phosphorylation or acetylation of NFB at different 
sites results in changes in NFB activity. Phosphorylation of NFB at Ser-529 
and Ser-536 stimulated NFB transactivation, whereas acetylation of NFB at 
Lys-218, -221 and -310 enhanced DNA binding of NFB [133]. Thus, factors 
that stimulate phosphorylation of acetylation of NFB at these sites may 
confer stimulation of NFB activity.  
If gelsolin activates NFB by either of the four above-menioned 
mechanisms, it would all result in enhanced NFB activity, which can be 
measured by dual-luciferase reporter assay. Therefore, dual-luciferase reporter 
assay was used to assess the effects on NFB instead of other indirect assays 
such as electrophoretic mobility shift assay (EMSA) or enzyme-linked 
immunosorbent assay (ELISA). 
As no changes in NFB expression were observed when gelsolin was 
overexpressed, or knocked down, it is possible to rule out the possibility (1). If 
gelsolin activates NFB via either mechanism (2) or (3), increased NFB 
nuclear translocation will be detected when gelsolin expression is enhanced. If 
gelsolin exerts its effect by directly modulating NFB post-translational 
modification (4), an increase of NFB activity but not NFB nuclear 
translocation will be observed.   As increased gelsolin translocation to nucleus 
was detected in gelsolin-overexpressing cells (data not shown), it is possible 
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that gelsolin activates NFB by enhancing nuclear translocation of NFB or 
by directly stimulating NFB activity in the nucleus. The possible influence of 
gelsolin on nuclear translocation of NFB can be determined by cytoplasmic 
and nuclear fractionation followed by Western blot. To investigate whether 
gelsolin directly stimulates NFB activity, further studies on the effects of 
gelsolin modulation on phosphorylation and acetylation of NFB are 
suggested. If gelsolin induces phosphorylation or acetylation at the positive 
regulatory sites of NFB, it suggests that gelsolin may stimulate NFB 
activity via direct post-translational modification of NFB, which induces 
enhanced DNA binding capacity or transactivation of NFB. 
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SUMMARY 
In this chapter, we showed that fibronectin expression in HCT 116 cells 
was stimulated by HGF. HGF in turn activated EGR-1 expression, which is a 
known regulator of fibronectin. Gelsolin upregulated fibronectin expression 
but not did not regulate EGR-1 expression nor activity. Therefore, fibronectin 
regulation by gelsolin is unlikely via gelsolin’s influence on EGR-1.  
On the other hand, TNF, a known stimulator of NFB, did not affect 
gelsolin levels but increased fibronectin expression in HCT 116 cells. Athough 
NFB expression was not affected by gelsolin overexpression, NFB activity 
was significantly enhanced in gelsolin-overexpressing cells and attenuated in 
several gelsolin knock-down cells. Moreover, upregulation of fibronectin by 
gelsolin could be attenuated by NFB inhibition. Taken together, these results 

















GENERAL CONCLUSIONS AND FUTURE WORK 
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5.1. GENERAL CONCLUSIONS 
In this study, we have identified a novel role of gelsolin in regulating 
fibronectin, an important ECM component, as well as one of the underlying 
mechanisms of that regulation.  
Firstly, we showed that gelsolin protected colorectal cancer HCT 116 
cells from apoptosis and promoted HCT 116 cell survival in an anoikis model. 
Gelsolin exerted the effects by upregulating fibronectin expression and 
secretion in HCT 116 cells. Conditioned media obtained from gelsolin over-
expressing cells protected HCT 116 cells against apoptosis, indicating that 
gelsolin-overexpressing cells secreted factors that promoted cancer survival. 
On the other hand, fibronectin expression and secretion, which were regulated 
by gelsolin, protected cancer cells against apoptosis and promoted the survival 
pathway through Akt signaling in the anoikis condition. Fibronectin also 
rescued the apoptotic effects of gelsolin knock-down in HCT 116 cells 
cultured in anoikis conditions. These findings elucidated the important roles of 
gelsolin in cancer cell survival by upregulating fibronectin.  
Secondly, our results suggested that gelsolin upregulated fibronectin 
expression in HCT 116 cells through activation of the transcription factor 
nuclear factor kappa B (NFB) pathway. Gelsolin stimulated NFB activity, 
although did not affect NFB expression. NFB activity was significantly 
enhanced in gelsolin-overexpressing cells and attenuated in gelsolin-
knockdown cells. Activation of NFB by tumor necrosis factor alpha 
(TNFleaded to increased fibronectin expression in HCT 116 cells, whilst 
inhibition of NFB attenuated fibronectin level. Additionally, upregulation of 
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fibronectin by gelsolin could be attenuated by NFB inhibition. Although the 
transcription factor early grow response protein 1 (EGR-1) was also involved 
in fibronectin regulation in HCT 116 cells, fibronectin upregulation by 
gelsolin was unlikely via EGR-1 pathway. Activation of EGR-1 by the 
hepatocyte growth factor (HGF) resulted in upregulation of fibronectin 
expression. However, gelsolin did not affect either EGR-1 expression or EGR-
1 activity. These findings suggest that gelsolin upregulates fibronectin 
expression via NFB but not EGR-1 pathway. 
In conclusion, our results demonstrated a role of gelsolin in upregulating 
the expression and secretion of fibronectin to promote tumor cell survival. 
Based on the above findings, we propose a model for the novel role of gelsolin 
in cancer cell survival as illustrated in Figure 5.1. Results from this study 
provide further insights into the mechanisms behind the important roles of 
actin cytoskeleton as well as gelsolin in tumor biology. The findings would 
contribute to understanding of how cancer cells modulate the 
microenvironment to favor tumor progression, and this understanding may 














Figure 5.1 Schematic illustration showing the summary of the key 
findings presented in this thesis. In HCT 116 cells, gelsolin stimulates NFB 
activity, which then upregulates fibronectin expression and secretion. Secreted 
fibronectin binds to integrin receptors, stimulates Akt activation, resulting in 
anoikis resistance and increased survival of cancer cells. Fibronectin 
expression is also upregulated by EGR-1 activation, but the effects of gelsolin 
on fibronectin expression is unlikely via EGR-1. 
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5.3. LIMITATIONS OF THE STUDY AND FUTURE WORK 
5.3.1. Limitations of the study 
In investigation of the effect of gelsolin on fibronectin expression and 
secretion, besides using gelsolin knockdown, it would be good if gelsolin is 
deactivated by either using inactive forms of gelsolin or using gelsolin activity 
inhibitors. These experiments would substantiate our findings that gelsolin 
regulates fibronectin expression and secretion. However, to our knowledge, 
there are no such inactive forms or activity inhibitors of gelsolin, and hence 
using gelsolin knockdown is the only choice at the moment.  
The second limitation of the study is that possible compensatory effects 
of other actin-binding proteins have not been studied. Despite the important 
roles of gelsolin in regulating different aspects of cellular biology, gelsolin 
knockout had no lethal effects on experimental animals, suggesting that 
gelsolin’s functions were compensated by other factors, such as other actin-
binding proteins. Our results also suggest similar possibility. When about 80% 
of gelsolin was knocked down, there was only about 40% suppression in 
fibronectin expression and secretion (Figure 3.4A&B). Therefore, when 
gelsolin is knocked down, there are probably compensatory effects of other 
actin-binding proteins, which have not been addressed in this study and 
deserve further investigations.  
In addition, we have shown that gelsolin promotes expression of 
fibronectin via NFB activation. However, it is not clear whether gelsolin 
enhances fibronectin secretion by only upregulating fibronectin expression or 
by promoting both fibronectin expression and exocytosis of fibronectin 
secretory vesicles. Given that gelsolin plays an important role in exocytosis of 
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insulin secretory vesicles due to its effects on actin dynamics, it is possible 
that gelsolin may influence exocytosis of fibronectin vesicles. Future studies 
could be extended to confirm this hypothesis. 
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5.3.2. Future work 
The following are key areas of interest for future investigations: 
(1) To investigate the underlying mechanisms of NFB activation by 
gelsolin:  
We have provided evidence showing that gelsolin activated NFB 
activity in HCT 116 cells. However, the mechanisms underlying gelsolin-
regulated NFB activity need to be elucidated. As gelsolin did not affect 
NFB expression, the increased NFB activity by gelsolin is possibly a result 
of  other reported mechanisms such as: (a) enhanced nuclear translocation of 
NFB, (b) suppression of NFB inhibitors or (c) direct stimulatory effects on 
nuclear NFB transcriptional activity [133]. We have detected increased 
gelsolin translocation in the nucleus in gelsolin-overexpressing cells (data not 
shown), suggesting possible involvement of gelsolin in nuclear translocation 
of NFB. To investigate this possibility, gelsolin expression in cells will be 
modulated by either overexpression or siRNA knock-down. Nuclear 
translocation of NFB will be measured by cytoplasmic and nuclear 
fractionation followed by Western blot. The nuclear translocation of NFB 
will also be visualized by live-cell imaging. If gelsolin exerts its effect on 
NFB by either mechanism (a) or (b), NFB translocation to the nucleus will 
be increased in gelsolin-overexpressing cells and attenuated in gelsolin-
knockdown cells. Nuclear translocation of NFB as well as possible co-
localization of gelsolin with NFB can also be studied by 
immunofluorescence microscopy. To investigate if gelsolin stimulates NFB 
by suppressing the NFB inhibitory proteins, IB (b), the expression, 
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phosphorylation and ubiquitination of IB will be measured. If gelsolin 
overexpression leads to decreased IB expression or increased IB 
phosphorylation or ubiquitination, this means that gelsolin activates NFB by 
increasing IB degradation. To investigate whether gelsolin directly enhances 
nuclear NFB transcription activity (c), further studies on post-translational 
modification of nuclear NFB upon modulation of gelsolin can be conducted. 
Phosphorylation of NFB at Ser-529 and Ser-536 were shown to stimulate 
NFB transactivation, and acetylation of NFB at Lys-218, -221 and -310 
enhanced DNA binding of NFB [133]. If overexpression of gelsolin induces 
phosphorylation or acetylation at the positive regulatory of NFB, whilst 
gelsolin knock-down exhibits the opposite effects, it means that gelsolin 
stimulates NFB activity via direct post-translational modification of NFB, 
which induces enhanced DNA binding capacity or transactivation of NFB. 
 
(2) To investigate if the actin-regulating functions of gelsolin are 
involved in regulating fibronectin secretion: 
Actin filaments at the proximity of plasma membrane serve as barriers 
against exocytosis of secretory vesicles. By severing actin filaments, gelsolin 
possibly disrupts the barriers for enhanced exocytosis. Thus, our study can be 
extended to examine whether gelsolin enhances fibronectin secretion by 
severing the actin cytoskeleton to facilitate the transport of fibronectin to 
plasma membrane for exocytosis. Deletion mutants of the gelsolin gene can be 
constructed, including deletion of domain G1, which is responsible for actin-
severing function and deletion of domains G1-3, which are responsible for 
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both actin-severing and capping functions of gelsolin. Cells will be transfected 
with plasmids containing either of the deletion mutants. Cells transfected with 
plasmids containing wild-type gelsolin and plasmids with empty vector will be 
used respectively as positive and negative controls. If secreted fibronectin is 
reduced in mutant gelsolin-expressing cells compared to wild-type gelsolin, it 
means that the actin-severing function of gelsolin is important in the secretion 
of intracellular fibronectin. Immunofluorescence studies will be conducted on 
cells transfected with either mutant or wild-type gelsolin to confirm the 
findings. The vesicle-SNARE protein synaptobrevin (VAMP2), which is 
normally coupled on secretory vesicles, will be used as a secretory vesicle 
marker. F-actin, fibronectin and secretory vesicles will be respectively stained 
with fluorescence-tagged phalloidin, fibronectin antibodies and VAMP2 
antibodies. Secretory vesicles of fibronectin will be identified by the co-
localization of fibronectin with VAMP2. If decreased depolymerization of 
actin filaments coincident with less secretory vesicles of fibronectin are 
observed at the proximity of plasma membrane of the mutant gelsolin cells 
compared to wild-type gelsolin cells, it indicates that gelsolin enhances 
fibronectin secretion by severing actin filaments and promoting actin turnover. 
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APPENDICES 
APPENDIX I. PLASMID CONSTRUCT FOR GELSOLIN OVER-
EXPRESSION 
1. Sequence of pIRES2-EGFP-gelsolin recombinant plasmid: 
Black: pIRES2-EGFP sequence; blue: gelsolin sequence cloned (2196 
nucleotides); underlined in red: EcoR I and Sac II sequences; start (ATG) and 
end (TGA) codons. The cytoplasmic gelsolin sequence matches that of 









































































































































2. Plasmid construct for stable expression of gelsolin in HCT 116 cells: 
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APPENDIX II. PREPARTION OF REAGENTS AND CHEMICALS 
Cell culture materials 
McCoy’s 5A Medium (1L) 
McCoy’s 5A powder (M4892, Sigma-aldrich)  
2.2g NaHCO3,  
100mL Fetal Bovine Serum  
Top up to 900mL MiliQ water and filter through 0.22µm filter 
membrane. 
RPMI-1640 (1L)  
RPMI-1640 powder (R4130, Sigma Aldrich) 
2g NaHCO3, 
100mL Fetal Bovine Serum 
Top up to 900mL MiliQ water and filter through 0.22µm filter 
membrane. 
Freezing media 
95% Fetal bovine serum 
5% DMSO 
 
Western blot materials  
Resolving gel for SDS-PAGE 
Distilled water 
30% bis-acrylamide 
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4% Stacking gel for SDS-PAGE 
Distilled water 
30% bis-acrylamide  




10X SDS-PAGE running buffer 
25mM Tris base 
192mM Glycine 
0.1% SDS 
10X transfer buffer for SDS-PAGE  
25mM Tris base, 
192mM Glycine 
0.025% SDS  
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